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Abstract 
Thymidine kinase 1 (ATP: thymidine 5’- phosphotransferase, EC 2.1.7. 21, TK1) is a 
cellular enzyme involved in salvage pathway for DNA precursor synthesis. TK1 
activity fluctuates during cell cycle, it reaches peak in S phase and absent in M phase. 
Because of its tight regulation with cell cycle, TK1 has been used as proliferation 
marker for diagnosis and treatment monitoring of various malignancies in human and 
veterinary medicine. TK1 levels can be measured by activity based or antibody based 
assays. 
   The main aim of the research described in this thesis was to develop TK1 antibody 
based assays for determining serum TK1 protein levels in comparison with TK1 
activity from dogs with different malignancies. Further analysis revealed a significant 
difference in the molecular forms of TK1 in sera from canine leukemia and mammary 
tumours.     
   In Study I, serum TK1 protein levels in dogs with different solid tumours were 
determined by using an antibody based assay i.e. immunoaffinity assay. TK1 protein 
levels were significantly higher in dogs with solid tumours than expected from the TK1 
activity values. In contrast, the specific activity of TK1 in sera from healthy dogs was 
2.5 fold higher than that of solid tumours. The molecular forms of recombinant, cellular 
and serum TK1 were investigated in study II. Dog recombinant and serum TK1 existed 
as oligomers with a molecular weight (MW) of 720-300 kDa. Cellular TK1 from both 
dogs and humans were mainly as tetramers. Human recombinant and serum TK1 
activity eluted in two peaks: one at high and one at low MW, corresponding to 720-300 
kDa and 200-50 kDa, respectively.  
   In study III, TK1 protein levels in sera from dogs with mammary tumours were 
determined by immunoaffinity assay. The TK1 protein assay differentiated mammary 
adenomas efficiently from healthy dogs, and adenomas from carcinomas, but this was 
not possible with the TK1 activity assay. In mammary tumour sera, active TK1 eluted 
as high MW oligomer similar to leukemia however, TK1 protein was detected not only 
as high MW form but also in the fractions where no TK1 activity was found. This 
indicates that serum TK1 exits in multiple forms in mammary tumours with a large 
fraction of inactive TK1 protein. Study IV describes the development of TK1-ELISA, 
based on a polyclonal and a monoclonal anti TK1 peptide antibodies, that was used to 
measure TK1 protein levels in dog sera. TK1 protein levels were significantly higher in 
sera from dogs with haematological tumours as well as solid tumours in comparison 
with healthy dogs. Overall, the results demonstrate that TK1 protein assays provide 
valuable diagnostic information in a variety of canine malignancies. 
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1.  Introduction 
 
1.1  Cancer 
 
Cancer is one of the most common diseases in humans and is a major cause of 
deaths. In 2012, it accounted for 14.6% of all human deaths according to World 
Health Report. Cancer development is a complex process that involves genetic 
abnormalities and loss of host defence. Only 5-10% of cancers are caused by 
genetic defects whereas a much larger proportion are due to environmental 
factors such as diet, infections, radiation, stress, alcohol and obesity. These 
factors may induce DNA alterations and loss of cell function that results in 
tumour growth (Anand et al., 2008). 
Carcinogenesis is a process during which normal cells are transformed into 
cancer cells. This process leads to an imbalance between cell proliferation and 
cell death, mainly due to accumulation of genetic mutations.  
In the process of carcinogenesis, a normal cell that becomes a tumour cell 
acquires six traits that are commonly observed in different cancers and are 
considered as the hallmarks of cancer: 
1) Self-sufficiency in growth signals 
2) Insensitivity to anti-growth signals 
3) Evasion of programmed cell death (Apoptosis) 
4) Limitless replicative potential 
5) Sustained angiogenesis 
6) Invasion and metastasis (Hanahan & Weinberg, 2000). 
7) Emerging are abnormal metabolic pathways and evading immune 
system (Hanahan & Weinberg, 2011). 
 
In normal physiological processes, cells require exogenous mitogenic signals 
for proliferation but tumour cells acquire the ability to generate growth factors 
or growth signals to which they are responsive via so called autocrine loops. 
The effect is not only due to autocrine secretions, but also sometimes due to 
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overexpression of receptors also makes cancer cells hyper-responsive to 
growth factors. Specific mutations in cancer cells can cause ligand independent 
signalling that switches the cell extra-cellular matrix (ECM) receptors in 
cancer cell to become more responsive to pro-growth signals, which leads to 
tumour self-sufficiency (Lukashev & Werb, 1998; Hanahan &Weinberg 2000). 
Loss of cell cycle regulation is also a common feature in many cancers. In 
general, cells divide in an orderly fashion according to the phases of the cell 
cycle. During G1 and G2 (gap phases), the cells are actively metabolizing but 
division cannot occur. Only in S (synthesis) phase, DNA replication result in 
chromosome duplication. During M (mitosis) phase, the chromosomes separate 
and the division of cytoplasm (cytokinesis) takes place. There are various 
checkpoints in the cell cycle at the end of G1 and G2 that can prevent the cell 
from entering S or M phases of the cycle. Cells that are not in the process of 
dividing are in the G0 stage, which includes most of adult cells (Fig 1A). The 
cell cycle is controlled by different check points that assess extra cellular 
signals, cell size and DNA integrity. Cyclins and cyclin dependent kinases 
(CDKs) are positive regulators which induce cell cycle progression and CDK 
inhibitors are negative regulators in the cycle. Deregulation of the cell cycle is 
a common phenomenon that occurs during tumour development (Hanahan & 
Weinberg, 2000).  
 
Cancer cells evade anti-proliferative signals by inhibiting the expression of 
integrins and other adhesion molecules that carry growth regulator signals. 
Furthermore, cancer cells have high expression of pro-growth signals resulting 
in limitless proliferation (Hanahan & Weinberg, 2000). Tumour cells avoid 
apoptosis in order to expand the tumour cell population and a common strategy 
to avoid apoptosis is down regulation of the p53 tumour suppressor gene. This 
results in inhibition of key components, which plays an important role for 
inducing the apoptotic cascade (Hanahan & Weinberg, 2000; Harris, 1996). 
Furthermore, tumour cells lose the capacity for senescence, leading to the 
limitless replicative potential of cancer cells often occurring by telomere 
shortening. This in turn upregulates the expression of the telomerase enzyme 
that adds hexanucleotide repeats to the ends of telomeric DNA. Telomere 
lengths are maintained above the threshold results in unlimited proliferation of 
descendant cells (Bryan et al., 1995; Hanahan & Weinberg, 2000).  
Another important feature of tumour cells is sustained angiogenesis. Initially 
tumour cells lack angiogenic ability and they acquire this ability via an 
angiogenic switch during tumour development. It occurs by changing the 
balance between angiogenesis inducers and countervailing inhibitors (Hanahan 
& Folkman, 1996). Many tumours had increased expression of angiogenesis 
inducers like vascular endothelial growth factor (VEGF) and fibroblast growth 
factors (FGFs) compared to normal tissues. The down regulation of 
endogenous inhibitors such as thrombospondin-1 or β-interferon is also more 
frequent in tumour tissues compared to normal tissues (Hanahan & Weinberg, 
2011). 
15 
Once the tumour cells acquire the ability to grow beyond limitations with 
sustained angiogenesis, results in invasion of primary tumour masses into the 
surrounding tissues. Through circulation of tumour cells to distant sites where 
they form new tumours, the metastatic process is established (Kawaguchi, 
2005; Sporn, 1996). However, at cellular level, the development of cancer 
consists of three steps: the first step is tumour initiation due to genetic 
alteration that is fixed by the cell doubling rate of a certain tissue. This often 
leads to abnormal proliferation of a certain tumour stem cell clone. The second 
step is outgrowth into a population from this clonally derived tumour cell. In 
the last step, tumour progression, which continues as additional mutations, 
occurs within the tumour population. Once the variant cells with mutations are 
established within the tumour population, results in clonal selection. This 
process continues throughout tumour development and leads to tumour 
metastasis in various tissues or organs (Fig 1B) (Hanahan &Weinberg, 2000; 
2011). 
 
 
 
 
Figure 1:  Cell cycle and carcinogenesis. A) Major events of cell cycle in different 
phases. B)  The process of cancer development. Cancer development occurs in three 
different steps 1) initiation 2) promotion and 3) progression. 
 
The subsequent chapters describe basic information about cancers in dogs and 
biomarkers for cancer detection, and the later chapters deal with thymidine 
kinase 1 (TK1) as a biomarker in more detail.  
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1.2  Cancers in dogs 
 
Cancer is a major problem in dogs and one out of four dogs will develop 
cancer before the age of 10 years. The prevalence of cancer has increased in 
recent years and a number of factors may contribute to this such as feeding 
habits, hormone imbalance and infections. All dog breeds are affected by 
cancer but some breeds have a higher risk for a particular type of cancer, 
suggesting an underlying genetic predisposition to cancer. Many studies have 
shown that the aetiology and pathogenesis of canine tumours are similar to 
those of human tumours in several aspects. This indicates that dogs may serve 
as a good comparative model for human diseases. (MacEwen, 1990; Vail & 
MacEwen, 2000). 
According to a Swedish insurance agency (AGRIA), 18% of dogs die each 
year from different types of malignancies (Bonnet et al., 2005). Another study 
showed that malignancies account for 23% of deaths in dogs (Jagielski et al., 
2002). Yet another study found that the incidence of cancer increases with 
increasing age and the risk of developing cancer increases from <1% at the age 
of one year to 7% at the age of nine years (Bonnett & Egenvall, 2010). Dogs 
are affected by different types of cancers which are classified based on 
histopathological examination as benign or malignant that in turn indicates the 
extent of tumour progression. Tumours are further classified based on the 
origin of tissue or cell (Table 1). The most common cancers in dogs include 
lymphomas, osteosarcomas, hemangiosarcomas, mammary tumours and mast 
cell tumours. Cancer incidence depends on breed, age, sex and environmental 
factors. Detection of tumours at early stages will help to extend the life span of 
patients by earlier treatment. 
Biomarkers are the substances found in the body when there is an alteration in 
normal body condition. According to the National Cancer Institute (NCI) a 
biomarker is defined as ‘a biological molecule found in blood, other body 
fluids, or tissues that is a sign of a normal or abnormal process or of a 
condition or disease’. Tumour biomarkers are not only useful for early 
detection and to determine the effectiveness of anti-cancer therapy but also 
help to predict the recurrence of malignant diseases (Henry, 2010). Different 
studies have been done to determine the diagnostic and prognostic values of 
various proteins and enzymes as biomarkers in canine malignancies. 
Commonly used tumour biomarkers in canine oncology are described in later 
sections. 
 
 
 
Table 1. Classification of tumours based on their origin (adopted from Withrow & 
McEwen’s Small Animal Clinical Oncology, 2nd Edn).  
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   Benign     Malignant 
 A) Epithelial 
   Squamous Squamous papilloma Squamous cell carcinoma 
 Transitional transitional papilloma Transitional cell carcinoma 
 Glandular Adenoma, cystadenoma Adenocarcinoma 
 Non glandular Adenoma Carcinoma 
 B) Mesenchymal 
   Fibrous tissue Fibroma Fibrosarcoma 
 Fat Lipoma Liposarcoma 
 Cartilage Chondroma Chondrosarcoma 
 Bone Osteoma Osteosarcoma 
 Muscle (smooth) Leiomyoma Leiomyosarcoma 
 Muscle (skeletal) Rhabdomyoma Rhabdmyosarcoma 
 Endothelial cells Hemangioma Hemangiosarcoma 
 Synovium - Synovial cell sarcoma 
 Mesothelium - Mesothelioma 
 Melanocytes Benign melanoma Malignant melanoma 
 Peripheral nerve Schwannoma Malignant schwannoma 
 
 
Neurofibroma neurofibosarcoma 
 C) Hematopoietic 
   Lymphocytes - Lymphoma, Lymphosarcoma 
 Plasma cells Cutaneous plasmacytoma Multiple myeloma 
 Granulocytes - Myeloid leukemia 
 Red blood cells - Erythroid leukemia 
 Macrophages Histocytoma Malignant histiocytosis 
 Mast cells 
 
Mast cell tumour 
 D) Brain 
   Glial cells Astrocytoma Astrocytoma 
 
 
Oligodendroglioma glioblastoma multiforme 
 Meninges Meningioma Malignant meningioma 
 E) Gonadal 
   Germ cells Seminoma, Dysgerminoma Seminoma, Dysgerminoma 
 Supportive cells Sertoli cell tumour Sertoli cell tumour 
 
 
Granulosa cell tumour Granulosa cell tumour 
 Interstitial cells Leydig cell tumour, thecoma 
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1.3  Biomarkers in Veterinary Medicine 
 
Based on their function during tumour development, biomarkers can be 
classified as 
 
I. Cell proliferation markers 
II. Apoptosis 
III. Matrix metalloproteinases (MMPs) 
IV. Angiogenesis 
V. Cell cycle regulators 
VI. Serum biomarkers 
I. Cell proliferation markers 
One of the main characteristics of tumour cells is uncontrolled proliferation 
and the rate of proliferation determines the aggressiveness of the tumour. 
Different methods have been developed to detect cell proliferation in tumours 
including mitotic index (MI), incorporation techniques, flow cytometry, in situ 
hybridizations and immunohistochemical methods. Proliferation markers such 
as Ki-67, proliferating cell nuclear antigen (PCNA) and argyrophilic nucleolar 
organiser region (AgNOR) are used to determine the proliferation rate in 
different dog tumours by immunohistochemical methods.  
Mitotic index (MI) 
The Mitotic index (MI) is an indirect measure of cell proliferation based on 
quantification of the fraction of mitotic cells as percentage of the total number 
of cells. Studies showed that MI can significantly differentiate benign from 
malignant canine mammary tumours (Preziosi et al., 1995) and MI is also 
useful to separate tumours with similar histological appearance, like canine 
basal cell carcinomas from squamous cell carcinomas (De Vico et al., 1994). In 
veterinary oncology, MI has been shown as a prognostic indicator for different 
tumours, including mast cell tumours, mammary tumours and melanomas 
(Bostock et al., 1989; Bostock, 1979; Sarli et al., 2002). A major concern with 
this method is variations in cell size and the difficulty in discriminating mitosis 
from necrosis by hematoxylin and eosin staining. 
Incorporation techniques (thymidine and bromodeoxyuridine) 
Thymidine incorporation is one of the earliest techniques used for determining 
cell proliferation. Later, thymidine was replaced by the analogue 
bromodeoxyuridine (BrDU) for measuring cell proliferation. BrDU is 
incorporated into DNA of S phase cells and it can be detected by 
immunohistochemistry or flow cytometry using BrDU antibodies. Some 
studies were done by using this method to measure the rate of cell proliferation 
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in dog tumours (Sakai et al., 2002; Yoshida et al., 1999). Furthermore, BrDU 
incorporation can be used to grade mast cell tumours in dogs based on 
aggressiveness (Sakai et al., 2002). The need to administer BrDU into living 
animals before analysis is a major drawback with this method. 
Ki-67 
Ki-67 is a non-histone nuclear protein which is present in all phases of cell 
cycle except in G0. However, during interphase Ki-67 is detectable only in the 
nucleus and it is relocated to the surface of chromosomes during mitosis. Even 
though it is detectable in all phases of the cell cycle, the highest level is found 
in G2 and M phase cells (Gerdes et al., 1983). The prognostic and diagnostic 
values of Ki-67 expression have been studied in different canine tumours. The 
Ki-67 index correlated with the histological grade of canine lymphomas and 
suggests that Ki-67 can be used for classification of lymphomas based on 
tumour aggressiveness (Fournel- Fenry et al., 1997). Furthermore, the Ki-67 
index could predict the duration of the relapse free interval after chemotherapy 
(Phillips et al., 2000). It is also a prognostic marker for dogs with mast cell 
tumour (Abadie et al., 1999). In canine mammary tumours, it was shown that a 
high Ki-67 index positively correlated with increased risk of metastasis, short 
disease free survival and overall low survival rates (Pena et al., 1998; Sarli et 
al., 2002; Zuccari et al., 2004). Even though Ki-67 has prognostic value, its 
clinical use in canine oncology has been limited due to sampling inconsistency, 
lack of standardized techniques and differences in immunostaining procedures. 
Proliferating cell nuclear antigen (PCNA) 
PCNA is a nuclear protein acting as a co-factor for DNA polymerase delta and 
plays an important role in DNA replication (Bravo et al., 1987). PCNA is 
produced in mid G1 phase and throughout S phase but it is detectable in all 
phases of cell cycle because of its long half-life. Higher concentrations of 
PCNA were observed throughout S phase, which correlates with DNA 
synthesis (Bravo et al., 1985). The prognostic value of PCNA was evaluated in 
different dog tumours. In case of mast cell tumours, disease free survival and 
overall survival time was longer in patients with low PCNA index (Simoes et 
al., 1994). Moreover, PCNA index is useful in grading mast cell tumours 
according to their aggression (Hung et al., 2000). For mammary tumours, the 
PCNA index did not relate significantly with metastasis, disease free survival 
and overall survival rates (Pena et al., 1998). In addition, the presence of 
PCNA during all cell cycle phases and its long half-life may give false positive 
results. 
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Argyrophilic nucleolar organiser region (AgNORs) 
AgNORs are a set of nucleolar proteins that are coded by ribosomal genes. In 
proliferating cells, the quantity of AgNORs progressively increases from early 
G1, reaches a peak in S phase and remains constant until the end of G2 (Sirri et 
al., 1999). Unlike other biomarkers described above, AgNORs does not 
measure the percentage of proliferating cells, but gives information about the 
rate of cell proliferation. AgNORs could provide valuable information in 
grading of canine lymphomas (Kiupel et al., 1998) and in the case of mast cell 
tumours, dogs with high levels of AgNOR had higher chance of tumour 
reoccurrence after surgical excision compared to dogs with low AgNOR. In 
addition, the overall survival rate was lower for dogs with high level of 
AgNOR (Abadie et al., 1999; Simoes et al., 1994). Similar results were also 
found in dogs with mammary tumours where high AgNORs was associated 
with short survival (Sarli et al., 2002). 
II. Apoptosis 
Another common feature of tumour growth is imbalance between tumour cell 
proliferation and cell death. Programmed cell death i.e. apoptosis plays an 
important role in tumour growth and aggressiveness because this process is 
deregulated during tumour progression. There are some studies published on 
the role of apoptosis for diagnosis and prognosis of canine tumours. Dogs with 
malignant mammary tumours had higher apoptotic indices compared to those 
with benign tumours and no correlation was observed between apoptotic 
indices and metastasis or tumour diameter (Funakoshi et al., 2000). Even 
though apoptosis plays a substantial role in several steps of carcinogenesis but 
its clinical value in canine oncology is still unclear. 
III. Matrix metalloproteinases (MMPs) 
Degradation of the extra cellular matrix (ECM) is crucial during progression of 
tumour diseases. Matrix metalloproteinases (MMPs) are zinc-dependent 
neutral endopeptidases, which hydrolyze protein and proteoglycan components 
of the ECM. Under physiological conditions, MMPs are expressed by a variety 
of cells and tissues. The MMPs are involved in a number of pathological 
processes that are responsible for accelerated ECM breakdown, which strongly 
correlates with tumour invasion and metastasis. The levels of MMPs have 
apparent clinical significance in malignant diseases. In different dog 
malignancies like mast cell tumours and mammary tumours, studies have 
shown higher levels of MMPs in neoplastic tissues compared to normal tissues 
(Leibman et al., 2000; Loukopoulos et al., 2003; Aresu et al., 2011). However, 
prognostic significance of MMPs in canine tumours is not clear.  
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 IV. Angiogenesis 
Development of new blood vessels from the existing vasculature is known as 
angiogenesis. It plays an important role in invasion and metastasis of solid 
tumours. Without angiogenesis, solid tumours cannot grow larger than 1-2 mm 
because tumour proliferation is limited by nutrient supply. Therefore, 
angiogenesis can be a prognostic indicator for tumour progression. The degree 
of angiogenesis is assessed by the intra-tumoural micro vessel density (IMD), 
which is a measure of the number of new intra-tumoural vessels in a neoplasm.  
IMD is significantly higher in malignant canine tumours, i.e. tumours with 
metastasis compared to benign tumours. IMD is also an independent prognostic 
factor for canine mast cell tumours (Preziosi et al., 2004). 
 V. Cell cycle regulators 
The uncontrolled cell proliferation of cancer cells is achieved by different 
alterations and mutations in cell cycle regulators. p53 is one of the most 
studied tumour suppressors in human and dog malignancies. Mutation in the 
p53 gene occurs commonly in different tumours and mutant p53 protein is 
more stable compared to wild p53 protein, as a sign of disrupted regulation of 
p53. Immunohistochemical studies of the p53 protein in canine tumours have 
shown over expression of p53 in malignant lymphomas and mast cell tumours 
(Jaffe et al., 2000; Sokolowska et al., 2005). Furthermore, p53 over-expression 
in dogs with mammary tumours correlated with short survival rates (Wakui et 
al., 2001).  
Most of these tumour biomarkers described above are measured in tissues by 
immunohistochemistry, which limits their clinical applicability. Some proteins 
and enzymes are present in the blood of patients with malignant diseases at 
elevated levels and thus can serve as convenient biomarkers. Basic facts about 
some of these markers were described below. 
VI. Serum biomarkers  
Lactate dehydrogenase (LDH) levels and C-reactive protein levels (CRP) have 
been studied in relation with canine malignancies. 
LDH is an enzyme found in most body tissues and it plays an important role in 
cellular intermediary metabolism. Tissue damage results in release of LDH into 
the blood stream. Several investigations have been done to determine the 
prognostic capacity of serum LDH in different canine malignancies. However, 
serum LDH levels were elevated not only in malignancies but also in several 
other conditions such as infections, which significantly limits its clinical value 
as a tumour biomarker (Nakamura et al., 1997; Zanatta et al., 2003; von Euler 
et al., 2006). 
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Acute phase proteins (APPs) are serum proteins released from the liver in 
response to infection, inflammation or trauma. APPs include C-reactive protein 
(CRP), haptoglobin and serum amyloid A (SAA). CRP is one of the APPs 
produced predominantly in the liver in response to pro-inflammatory 
cytokines. Serum CRP levels are used as a biomarker of systemic inflammation 
and its levels correlate with severity and duration of the inflammatory stimuli. 
Serum CRP levels are elevated in different malignancies but they are also 
elevated in variety of diseases with systemic inflammation (Nakamura et al., 
2008). Recent study showed an alternative way to use serum CRP as a marker 
in combination with thymidine kinase 1 (TK1, see below) by creating a 
neoplastic index (NI). Evaluation of NI in dogs with different tumours 
apparently differentiates those with malignancy from healthy dogs more 
effectively than either of the two markers alone (Selting et al., 2013).  
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2. Overview of DNA precursor synthesis 
 
Nucleic acids are the intracellular molecules that store the genetic information 
in the form of DNA or RNA. Nucleotides are the building blocks of DNA or 
RNA, which are involved in various functions such as DNA replication, 
transcription, and protein synthesis, as well as DNA repair. Nucleotides are 
composed of a nitrogenous base, a five-carbon sugar (ribose/deoxyribose), and 
one to three phosphate groups. The nucleotides are subdivided into two 
families: the purine bases including adenine (A) and guanine (G) and the 
pyrimidine bases include cytosine (C) thymine (T) and uracil (U). Thymine is 
only found in DNA whereas uracil is found in RNA. The five-carbon sugar is 
either a ribose in RNA, or a 2-deoxy ribose in DNA. The attachment of one 
phosphate group to the 5-hydroxyl group of pentose sugar forms a nucleoside 
monophosphate (NMP/dNMP), further addition of a second and a third 
phosphoryl groups to NMP results in nucleoside diphosphate (NDP/dNDP) and 
triphosphate (NTP/dNTP), respectively. DNA precursors are synthesized by 
two pathways, either the de novo or the salvage pathway. 
 
 
2.1  The de novo pathway 
 
In the de novo pathway, both purines and pyrimidines are synthesized from 
small molecules such as amino acids, phosphoribosyl pyrophosphate (PRPP) 
and CO2, through reactions that involve many enzymes. The initial product 
during purine biosynthesis is IMP (inosine 5-monophosphate), which is later 
converted into AMP (adenosine 5-monophosphate) or GMP (guanosine 5-
monophosphate). These ribonucleoside phosphates (NMPs) are further 
phosphorylated to di phosphates (NDPs) and tri phosphates (NTPs) for RNA 
synthesis. NDPs are reduced to deoxyribonucleoside diphosphates (dNDPs) by 
ribonucleoside reductase (RNR). The dNDPs undergo phosphorylation forming 
the dNTPs (Fig 2) (Nordlund & Reichard, 2006; Reichard, 1988: Thelander & 
Reichard, 1979). In a special section of the de novo pathway, dTMP is 
synthesized from dUMP via thymidylate synthase (TS). dTMP is further 
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phosphorylated into dTTP, which serves as DNA precursor (Montfort & 
Weichsel, 1997). 
 
 
Figure 2: Synthesis of DNA precursors in the cytosol and mitochondria. The synthesis 
of dNTPs occurs by two pathways, ribonucleotide reductase (RNR) dependent de novo 
synthesis in the cytosol and salvage of deoxyribonucleosides, performed by kinases in 
the cytosol and mitochondria (Adopted from Saada, 2009). 
 
2.2  The salvage pathway 
 
This is an alternative pathway in which deoxyribonucleosides (dNs) from 
degraded DNA or from food are used as precursors. It is a complement to the 
de novo synthesis in all animal cells. The dNs are phosphorylated to dNMPs 
by deoxyribonucleoside kinases resulting in trapping of the nucleotides inside 
the cell (Fig 2). This step is often rate limiting in the salvage pathway (Arner 
& Eriksson, 1995). Similar to the de novo pathway, dNs are subsequently 
phosphorylated by NMPKs and NDPKs, forming dNTPs, which are used for 
DNA replication and repair (Fig 2) (Arner & Eriksson, 1995). 
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3.  Deoxyribonucleoside kinases (dNKs) 
 
dNKs are rate determining enzymes during nucleotide salvage by catalyzing 
the phosphorylation of deoxyribonucleoside to deoxyribonucleoside 
monophosphate (dNMPs). Nucleoside triphosphates act as phosphate donor. 
In mammals, there are four dNKs with overlapping substrate specificities. The 
dNKs include thymidine kinase 1(TK1), deoxycytidine kinase (dCK), 
thymidine kinase 2 (TK2) and deoxyguansine kinase (dGK). TK2 and dGK 
are mitochondrial enzymes whereas TK1 and dCK are cytosolic. Based on the 
amino acid sequence the dNKs are divided into two groups: the TK1 group 
and dCK, dGK and TK2 group (Eriksson et al., 2002). dNKs are of medical 
interest because they are involved in several human diseases. For example 
mitochondrial dNKs are needed for maintenance of mitochondrial DNA 
function and deficiency of either TK2 or dGK results in tissue specific 
mitochondrial DNA depletion syndrome (MDS) leading to severe myopathy, 
hepato/neuropathy and progressive external opthalmoplegia (Ronchi et al., 
2012; Tyynismaa et al., 2012; Wang, 2010; Eriksson et al., 2002).  
dNKs also plays important role in anti-viral and anti-cancer therapy since 
many of the anti-viral drugs are nucleoside analogs (NAs). These NAs are 
activated by dNKs to nucleoside analogue monophosphates (NAMP), and 
after further phosphorylation to their triphosphate forms they can be 
incorporated into viral or cellular DNA and interfere with viral DNA 
synthesis leading to blocked viral infection (Leoni et al., 1998). Moreover, 
dNKs are used in suicide gene therapy, in which a nucleoside kinase gene is 
inserted and expressed in target cells, and after treatment with NA and 
formation of NATP, which interferes with DNA replication resulting in cell 
death. Several experimental studies have been done using this concept for 
cancer treatment, based on herpes simplex virus (HSV) type 1-TK gene 
(Sterman et al., 2005; Ural et al., 2000). 
 
In the next section basic properties of the four mammalian dNKs are 
described with focus on thymidine kinase 1 (TK1). Based on the subcellular 
location, dNKs are classified as mitochondrial dNKs and cytosolic dNKs. 
26 
 
3.1  Mitochondrial deoxyribonucleoside kinases (dNKs) 
 
Thymidine kinase 2 (TK2, E.C. 2.7.1.21) 
  
Thymidine kinase 2 (ATP: thymidine 5’-phosphotransferase) is a 
mitochondrial thymidine kinase that catalyzes the phosphorylation of 
deoxythymidine (dT), the same substrate for TK1. However, TK2 differs 
from TK1 in substrate specificity by phosphorylating dCyd (deoxycytidine) 
and its analogs to the corresponding 5’-monophosphates using ATP or CTP as 
phosphate donors (Eriksson et al., 2002; Munch-Petersen et al., 1991). The 
TK2 gene is 45 kb with 10 exons varying in size from 32 bp to 1304 bp and it 
is located on chromosome 16q22 (Eriksson et al., 2002). TK2 is 
predominantly localized in mitochondria and expressed in all tissues (Munch-
Petersen, 2010; Wang & Eriksson, 2000). TK2 levels are low in proliferating 
cells compared to TK1 but in non-proliferating cells TK2 is the only deoxy 
ribonucleoside phosphorylating enzyme (Eriksson et al., 2002). TK2 plays an 
important role in continuous and balanced supply of dNTPs for mitochondrial 
DNA replication and possibly nuclear DNA repair in resting cells (Wang et 
al., 2003).  
TK2 exits in variable forms from monomers to hexamers. Early studies 
described TK2 as a dimer with a molecular weight (MW) of 70 kDa (Lee & 
Cheng, 1976). Later studies with full-length recombinant mouse TK2 showed 
that it was an active dimer of about 60 kDa (Wang & Eriksson, 2000). 
However, more recent gel filtration analysis of human recombinant TK2 
demonstrated that it was a dimer, which oligomerized to form high MW 
complexes. However, it is still unclear which form of TK2 is present in vivo 
(Sun et al., 2010). TK2 is also able to phosphorylate several nucleoside 
analogs used in anti-viral and anti-tumour therapies, such as 3’-azido-2’-
deoxythymidine (AZT), arabinofuranosyl thymidine and 3’-fluoro- 2’, 3’- 
dideoxythymidine but at varying and often very low rates. The kinetics of 
TK2 differs depending on the substrate, i.e. TK2 phosphorylates 
deoxythymidine with negative cooperativity but with deoxycytidine (dCyd) 
and deoxyuridine (dUrd) it follows Michaelis-Menten kinetics (Wang et al., 
2003; Munch-Petersen et al., 1991). Genetic mutations in TK2 is associated 
with heterogeneous myopathic form of MDS, especially two missense 
mutations His90Asn and Ile181Asn result in skeletal myopathy, 
mitochondrial DNA (mt DNA) depletion and death at early age (Moreas et al., 
1991). Later, TK2 knock out mice was generated to understand the 
physiological role of TK2 in MDS. Immediately after birth mice showed 
progressive reduction of mt DNA, especially in skeletal muscles, brain, heart 
and liver. They died within 2-4 weeks, most likely due to unbalanced 
mitochondrial dNTP pools those result in MDS (Akman et al., 2008). 
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Deoxyguanosine kinase (dGK, E.C. 2.7.1.113) 
 
dGK (NTP: deoxyguanosine 5’-phosphotransferase) is another mitochondrial 
enzyme involved in phosphorylation of purine deoxyribonucleosides using 
NTP as phosphate donor. Thus, via the combined action of TK2 and dGK all 
four deoxyribonucleosides can be phosphorylated in order to supply building 
blocks to mtDNA synthesis. Similar to TK2, dGK is constitutively expressed 
in most tissues, and the amount of dGK generally correlates to the amount of 
mitochondria (Wang & Eriksson, 2003; Eriksson et al., 2002; Arner & 
Eriksson, 1995). Human dGK is encoded by a 32 kb gene with 7 exons located 
on chromosome 2q13. The active enzyme is homodimer with MW of 60 kDa 
(Wang et al., 1996; Wang et al., 1993). Normally dGK is located in 
mitochondria but it relocates to the cytosol during apoptosis in an apparently 
similar process as cytochrome C. The role of dGK in apoptosis is still unclear; 
it may be involved in activation of apoptotic nucleotide co-factors after re-
localization to the cytosol (Jullig & Eriksson, 2001). Like other dNKs, dGK is 
able to phosphorylate several purine analogs efficiently (Sjoberg et al., 1998). 
dGK and dCK show similarity in the amino acid sequence and have 
overlapping substrate specificity for analogs such as 2-chlorodeoxyadenosine, 
arabinosyl guanine, and 2’, 2’- difluorodeoxyguanosine (Munch-Petersen & 
Piskur, 2007). dGK most likely plays an important role in activation of certain 
analogs in tissues, where deoxycytidine kinase (dCK, see below) activity is 
low. dGK deficiency is associated with another form of MDS i.e. the hepato-
cerebral form which leads to severe liver failure with or without neurological 
impairment along with rotary nystagmus and hypotonia (El-Hattab & Scaglia, 
2013; Suomalainen & Isohanni, 2010; Poulton et al., 2009). 
 
3.2  Cytosolic deoxyribonucleoside kinases (dNKs)  
 
Deoxycytidine kinase (dCK, E.C. 2.7.1.74)  
 
Deoxycytidine kinase (dCK, NTP: deoxycytidine 5’-phosphotransferase) is a 
cytoplasmic enzyme that phosphorylates purine and pyrimidine 
deoxyribonucleosides to their corresponding monophosphates by using 
nucleoside triphosphates such as ATP or UTP as phosphate donors (Eriksson 
et al., 2002). dCK expression varies in different tissues, i.e. it is high in 
lymphoid tissues, intermediate in proliferating cells of colon and mucosa, and 
low in differentiated tissues such as liver, muscle and kidneys. Human dCK is 
encoded by single copy gene of 34 kb located on chromosome 4 band q13.3-
21.1 with 7 exons that varies in size from 90 to 1544 bp. dCK is a homo 
dimer with an identical polypeptide of 261 amino acids and MW of 30 kDa of 
each (Song et al., 1993; Bohman & Eriksson, 1988). dCK expression is 
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regulated most likely by both post-transcriptional and post-translational 
mechanisms (Hazra et al., 2011; Eriksson et al., 2002; Arner & Eriksson, 
1995).  
dCK phosphorylates deoxycytidine more efficiently than deoxyadenosine 
(dA) and deoxyguansine (dG). The enzyme does not follow Michaelis-
Menton kinetics but shows negative co-operativity. It has broad range of 
substrate specificity and phosphorylates several nucleoside analogs that are 
important in anti-viral and anti-cancer therapy such as β-L-2´-3´- dideoxy-3´- 
thiacytidine (lamivudine), 2- chlorordeoxyadenosine (cladribine) and 
diflurodeoxycytidine (gemcitabine), 2-fluoro-arabinofuranosyl adenine 
(fludarabine), 2´-3´-dideoxycytidine (zalcitabine) and arabinosyl adenine 
(vidarabine) (Sabani et al., 2003; Eriksson et al., 2002; Eriksson et al., 1991). 
In order to understand the biological function of this enzyme, Toy et al. 
created dCK knock out mice and the mice exhibited impaired T and B 
lymphocytes production but other organs and tissues were not affected (Toy 
et al., 2010). Another similar study by Austin et al who reported that dCK 
knock out mice showed replication stress i.e. DNA replication was arrested in 
early S phase of T and B lymphoid cells. This provides a connection to the 
high dCK activity in lymphoid tissues, correlating with the symptoms in the 
knock out mice model (Austin et al., 2012).  
 
Thymidine kinase 1 (TK1, E.C. 2.7.1.21) 
 
Thymidine kinase 1 (ATP: thymidine 5’- phosphotransferase, EC 2.1.7. 21) is a 
salvage pathway enzyme that converts deoxythymidine (dT) to deoxy 
thymidine monophosphate (dTMP) by transferring the γ- phosphate group from 
ATP. dTMP subsequently phosphorylates into deoxythymidine diphosphate 
(dTDP) and deoxythymidine triphosphate (dTTP), which further incorporates 
into DNA. The dTTP in turn regulates TK1 action by negative feedback and 
this may be a rate-limiting step in DNA precursor synthesis (Eriksson et al., 
2002; He et al., 2002; Munch-Petersen, 2009). TK1 has narrow substrate 
specificity since it phosphorylates only dT and dUrd, whereas other dNKs have 
broader substrate specificities. 
TK1 activity is absent in resting cells but in proliferating cells, TK1 is cell 
cycle regulated. It reaches a peak at late G1, early S phase and is drastically 
reduced to undetectable levels at the end of mitosis (Sherely & Kelly, 1988). 
Because of its association with DNA synthesis and the S phase of the cell 
cycle, TK1 has been used as proliferation marker since the very early days of 
cell biology. TK1 activity measurements have also been used as a biomarker 
for prognosis and monitoring of treatment for cancer diseases in humans and 
dogs. TK1 has been studied extensively in many aspects i.e. enzyme structure, 
cell cycle regulation, substrate kinetics and as a biomarker in different 
malignant diseases which will be described in detail below. 
 
 
29 
 
 
 
 
 
 
 
 
 
 
 
4. Thymidine kinase 1 (TK1) 
 
4.1  TK1 sequence  
 
The first human thymidine kinase cDNA was cloned and characterized 30 
years ago (Flemington et al., 1987; Bradshaw & Deininger, 1984). TK1 is 
located on chromosome 17 and the cDNA is 1241 bp, with an open reading 
frame of 702 bp coding for a protein of 234 amino acids.  
 
TK1 exits as homodimer or homotetramer with a sub-unit size of 25.5 kDa 
(Munch-Peterson et al., 1993). Human TK1 shares higher sequence identity 
with TK1 from different mammals where most of the N-terminal is conserved 
and diversity confined to the C-terminal region. When the human TK1 
sequence is compared to the dog TK1 sequence, the primary amino acid 
sequences are highly homologous in the N-terminal with an identity of 89.5% 
and the diversity (about 10%) occurs in the C-terminal 40 amino acids. 
Furthermore, human TK1 contains 11 cysteines whereas canine TK1 contains 8 
cysteines. The extra cysteines in human TK1 that are absent in dog TK1 are 
shown in Fig 3 as blue circles.  
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Figure 3. Alignment of the sequences from human TK1 (PO4183) and dog TK1 
(XM_540462). The secondary structures of human TK1 are marked above in the 
alignment are from Welin et al, 2004 (see also Fig 4). Blue circles show the cysteines 
difference between human and dog, (*) identical residues, (.) semi conserved residues. 
The alignment was done with the Clustal Omega program. 
 
4.2  TK1 structure 
 
The crystal structure of Human and Ureaplasma urealyticum TK1 was 
resolved by Welin et al in 2004. Several earlier attempts to solve the crystal 
structure of human TK1 were unsuccessful. The difficulty in solving the TK1 
structure was most likely due to the flexible ends of enzyme and when the C-
terminal 41 amino acids were truncated it was possible to obtain suitable 
crystals (Bringer et al., 2005; Welin et al., 2004). The truncated enzyme retains 
its enzyme activity as shown (Kauffman & Kelly., 1991). Furthermore, 
truncated TK1 could be stabilized by adding the feedback inhibitor dTTP 
(Welin et al., 2004). Human TK1 crystalizes as a tetramer and each subunit 
contains two domains (α/β), and a zinc-binding lasso like domain. The active 
site of the enzyme lies in between these domains (Fig 4A & 4B).  
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Figure 4. Structures of human TK1 (hTK1), PDB code: 1XBT. (A) Monomer and (B) 
tetramer structures of hTK1 (C) Dimer one connected by Interface-I, is the most stable 
dimer (D) Dimer two connected by interface-II, is the weak dimer, and interface-II 
separates upon dimerization of the tetramer (Welin et al., 2004). 
 
The α/β domain contains six parallel β sheets, which are surrounded by five α 
helices, along the α-helix and the flexible loop on one side, the remaining three 
short α-helices lie on the other side (Fig 4A). The α/β domains of TK1 are 
different from other dNKs and similar to the ATP binding domains of the Rec 
A-F1 ATPase family proteins (Welin et al., 2004). The zinc-binding domain 
consists of two perpendicular β ribbons and a lasso loop that covers the 
substrate binding site of TK1, and they are kept together by the zinc ion, which 
is coordinated by the two cysteine pairs (153, 155; 186, 188). This region is 
involved in forming the substrate binding site, thus this site may be sensitive to 
changes in the redox environment of cells (Birringer et al., 2005; Welin et al., 
2004). Zinc has significant role in TK1 expression and it was demonstrated by 
Ishikawa et al that both TK1 expression and the percentage of S phase cells are 
significantly lower when rats are fed with a diet of 50% reduced zinc compared 
to controls (Ishikawa et al., 2008).  
In the TK1 dimers, there are two different monomer-monomer interfaces 
labelled as strong and weak (Fig 4C and 4D). The weak interface is stabilized 
indirectly, whereas the strong interface is stabilized directly by ATP through 
many polar interactions (Segura-Pena et al., 2007). When the substrate binds 
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to the TK1 enzyme, most of the changes occur in the conformation of the lasso 
loop and the P loop, and these conformation changes depend on the substrate 
(Segura-Pena et al., 2007b; Welin et al., 2004). The small P loop consists of 
amino acid residues Gly26-Ser33 in hTK1, where the phosphate from ATP 
binds: once ATP binds to the P loop it becomes rigid and forms a β-hairpin 
structure (Segura-Pena et al., 2007 b; Birringer et al., 2005; Welin et al., 2004). 
The interaction between the phosphate-binding site in the loop and ATP is 
stabilized by a magnesium ion, which is surrounded by the phosphate groups of 
ATP and a threonine residue (Segura-Pena et al., 2007a; Welin et al., 2004). 
Phosphorylation of dT to dTMP by TK1 requires coordination of several amino 
acid residues where the lasso loop is stabilized by dT. Glu98 acts as base which 
accepts a proton from dT and Lys 32 transfers the phosphate group to dT and 
the conversion is stabilized by Arg60 (Birringer et al., 2005; Segura-Pena et 
al., 2007a; Welin et al., 2004). As we mentioned earlier, cysteines in TK1 are 
important for zinc ion co-ordination. Differences in cysteines between different 
species can change the enzyme behaviour. 
 
 
                                                                      
Figure 5. A model of Human TK1 (A) tetramer (B) monomer. Cysteines that are 
exposed on surface are indicated in yellow colour (provided by M.Welin based on 
sequence alignments and the structure data from Welin et al., 2004). 
 
For example, Human TK1 contains 11 cysteines whereas canine TK1 contains 
8 cysteines. Four of these cysteines in both human and dog plays an important 
role in coordinating the Zn2+ ion and some of them may be involved in 
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disulfide bridges between the TK1 polypeptides. A 3D model of the structure 
of full-length human TK1, constructed by M Welin based on sequence 
alignments and the structure of Ureaplasma TK, illustrates the likely position 
of the surface exposed cysteines in the tetrameric and monomeric forms of 
human TK1 (Fig 5). Cysteine 206 in the very C-terminal part of human TK1 
(Fig 5B) is a likely candidate for forming disulfide bridges with other exposed 
cysteine in TK1 or with other interacting protein partners. The extra cysteine 
206 in the C-terminal of human TK1 is most likely valine 211 in canine TK1 
(Fig 3). 
However, ATP binding induces over-all conformational changes in the TK1 
structure, and TK1 switches from a dimer of 50 kDa to a tetramer of 100 kDa. 
This switch is reversible and the transformation from dimer to tetramer can 
occur in the presence of UTP, GTP, and CTP instead of ATP, indicating that 
only the phosphate group is involved in the reversible tetramerization (Munch-
Petersen et al., 1993; Kuriowa et al., 2000; Munch-Petersen et al., 2009). The 
tetramerization has significant effects on the TK1 enzyme kinetic behaviour 
and the catalytic efficiency of the active tetramer increased 30 fold compared 
to the dimer (Munch-Petersen et al., 1995; Jensen & Munch-Petersen, 1994). 
Binding ATP also induces a transformation of a closed inactive dimer to an 
active more open tetramer form (Segura-Pena et al., 2007). The deletion of the 
C-terminal from TK1 enzyme did not significantly effect the reversible 
tetramerization induced by ATP (Li et al., 2004). On the other hand, Serine 13 
has differential effect on TK1 enzyme activity; a mutation of Serine 13 to 
Alanine did not alter the enzyme activity, whereas substitution of Serine 13 
with Asparagine decreased the TK1 activity and disrupted the ATP dependent 
tetramerization (Li et al., 2004).  
The transformation of dimer to tetramer was not only dependent on ATP but 
also on TK1 enzyme concentration. Recombinant TK1 concentration higher 
than 0.2 mg/mL induces the dimer to tetramer switch, and oligomerization was 
seen at high enzyme concentration, irrespective of ATP (0.4-20 mg/mL) (Fig 
6A) (Munch-Petersen et al., 2009; Birringer et al., 2006). This process also 
depends on enzyme modifications in vitro because immediate analysis after 
preparation showed TK1 as tetramer even at a low concentration of the protein. 
However, if the same sample was diluted and stored for 2 weeks before 
analysis, TK1 was a dimer (Munch-Petersen et al., 2009). The transformation 
of TK1 from dimer to tetramer does not occur in all organisms. In the case of 
bacteria, plants and dictyostelium TK1 exists only as dimer whereas in C. 
elegans and in all vertebrates TK1 is predominantly a tetramer. The regulatory 
switch of TK1 from dimer to tetramer is functional only in birds and mammals, 
which indicates a structural evolution of TK1 from a dimer form to a tetramer 
complex in certain organisms (Mutahir et al., 2013).  
Initial studies have been done to determine the molecular forms of cellular 
TK1 isolated from the human lymphocytes. The molecular weight of native TK 
ranged from 70-75 kDa in the absence of ATP, whereas in presence of 2 mM 
ATP it increased to 170-200 kDa (Munch-Petersen, 1984). Later, Karlstrom et 
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al. reported that cellular TK1 from proliferating HeLa cells was only found as 
a 58 kDa enzyme. The differences in the cellular forms of TK1 in these studies 
are most likely due to difference in the conditions during preparation and 
source of enzyme. 
 
 
 
Figure 6. (A) Effects of ATP on concentration depend tetramerization of TK1 (B) 
Fluctuations in TK1 protein and mRNA levels during different phases of the cell cycle 
(adopted from Sherley & Kelly, 1988; Munch-Petersen et al., 2009; Birringer et al., 
2006). 
 
4.3  TK1 control mechanisms 
 
The activity of TK1 is cell cycle dependent and it fluctuates during the 
different phases as follows: TK1 activity is very low in G1 phase, starts 
increasing at the end of G1 and reaches a peak during S phase. In S phase, TK1 
increases up to 10-15 fold compared to that in G1 phase cells. In comparison 
the amount of TK1 mRNA expression shows less cell cycle fluctuation (about 
3 fold). Finally, TK1 protein is degraded during late G2/M phase (Fig 6B) 
(Sherely & Kelly, 1988; Kauffman & Kelly, 1991). Phosphorylation is one 
common mechanism that targets cell cycle regulated proteins and it was 
reported that TK1 is heavily phosphorylated in dividing cells and it is hypo-
phosphorylated in M phase arrested cells. Thus, phosphorylation may play a 
role in TK1 regulation (Chang et al., 1994; He et al., 1996; Lin et al., 2003). 
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The half-life of TK1 protein changes drastically from 40 h to 1-2 h during M 
phase due to degradation of TK1 protein so that newly divided cells have very 
low or no TK1 (Sherely & Kelly, 1988). The ubiquitin-proteasome pathway is 
the main mechanism that regulates cell cycle protein levels. SCF (Skp, 
Cullin/CDC53 and F box) and APC/C (anaphase promoting complex/ 
cyclosome) are the two ubiquitin ligases that play a role in targeting proteins 
for cell cycle dependent proteolysis.  
Under normal conditions, TK1 is polyubiquitinylated at the G2/M interface and 
becomes target for the APC/C degradation pathway. Cdh1 is one of the two 
activators for the APC/C mediated ubiquitinylation which forms a complex and 
the APC/C-Cdh1 complex recognizes either a D box or a KEN box in the 
target proteins (Ke et al., 2004). In the TK1 sequence, a KEN box (residues 
203-205 in the human sequence) is conserved in mammals and plays a key role 
in the mitotic degradation of TK1. The Cdh1 interaction with the KEN box is 
the rate limiting step for the initiation of this degradation (Ke et al., 2004).  
Furthermore, Cdh1 mutant has blocked TK1 degradation but this was not 
observed with the Cdc20 mutant, the other activator of APC/C. Thus, TK1 is 
degraded via the APC/C-Cdh1 complex (Ke et al., 2004). This degradation 
process does not occur when dT binds to TK1 (Ke et al., 2007). Although 
APC/C-Cdh1 mediated degradation explains the mechanism for the low levels 
of TK1 in G0/G1 cells, transcriptional control via the E2F pathway is 
apparently responsible for the rapid increase of TK1 levels in S phase (Ke et 
al., 2004). However, it is likely that the TK1 regulatory switch from inactive 
dimer to active tetramer is fine-tuned not only by the levels of TK1 protein but 
also the ATP concentration as discussed previously and this mechanism helps 
to provide a balanced supply of dTTP for DNA replication (Munch-Petersen et 
al., 1995; Munch-Petersen et al., 1993).  
The phosphorylation of Serine-13 apparently prevents the ATP induced 
tetramerization of TK1 (Li et al., 2004). Since cdc2 kinase phosphorylates 
Serine-13 of TK1 in G2/M phase and this phosphorylation regulates TK1 
activity levels, leading to inactive TK1 dimers in S phase (Chang et al., 1998; 
Chang et al., 1994). The truncation of 44 C-terminal amino acids increased the 
TK1 half-life to 500 min compared to 80 min for wild type TK1 (Zhu et al., 
2006). This increased half-life of truncated TK1 demonstrates the role of the C-
terminal region (i.e. the KEN box) in TK1 degradation. Mutations in the TK1 
binding sites of ATP or dT result in an unstable protein with decreased half-life 
(Posch et al., 2001). 
TK1 is also subject to transcriptional control, not only post-translational 
modifications as described previously. G quadraplex motifs have been reported 
to suppress the promoter region of TK1 located between -13 to +8 relative to 
the transcription start site (TSS) (Basundra et al., 2010). The cell cycle 
regulatory unit (CCRU) was a 70 bp region between -133 and -64 relative to 
TSS in the promoter region of TK1. Especially, a 20 bp region from -84 to-64 
in CCRU is important because it contains an inverted CCAAT sequence and 
one GC rich motif, and without this 20 bp region transcription drops to barely 
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detectable levels (Kim & Lee, 1991; Kim & Lee et al., 1992). In addition, 
increased binding of cyclin A/p 107 during S phase correlates with increased 
TK1 mRNA expression (Li et al., 1993). Another protein that is involved in the 
cell cycle dependent TK1 expression is the CCAAT binding protein which 
binds to CCAAT sequence in the promoter region of TK1, contributing to the 
promoter strength (Lipson et al., 1995; Good et al., 1995). Thus, both the 
transcriptional and post-translational regulation plays an important role in 
regulation of TK1. 
 
4.4  Physiological role of TK1 
 
TK1 is closely associated with dTTP biosynthesis during the cell cycle as well 
as in DNA repair. Several studies have shown that TK1 levels increases when 
DNA is damaged by radiation or by chemotherapeutic agents (Chen et al., 
2010; Haveman et al., 2006). Tumour suppressor p53 activation in response to 
DNA damage is most likely a factor important for TK1 regulation because 
normal p53 function is required for cell cycle dependent TK1 expression, and 
loss of the p53 function results in a compensatory increase in TK1 
(Radivoyevitch et al., 2012; Schwartz et al., 2004). In relation to this, cellular 
TK1 levels increase upon DNA damage in p53-/- tumour cells but not in p53 
wild type cells (Chen et al., 2010). Furthermore, growth of tumour cells was 
not effected by TK1 knockdown even though the levels of dTTP decreased 
significantly. This confirms that the TK1 plays a substantial role is DNA repair 
rather than production of sufficient levels of dTTP for replication and cell 
growth (Chen et al., 2010). During DNA damage, TK1 not only interacts with 
p53 but also with p21, where overexpression of TK1 prevents the reduced cell 
growth because of p21 dependent growth suppressors (Huang et al., 2001). In 
this way, TK1 constitutes a resistance mechanism for the survival of tumour 
cells and depletion of TK1 during DNA recovery results in cell death (Chen et 
al., 2010). 
TK1 has a significant role in the immune system because the TK knockout 
(TK-/-) mice exhibited kidney abnormalities, significantly decrease number of 
splenic lymphocytes, abnormal lymphoid structure of the spleen and occasional 
inflammation of arteries (Dobrovolsky et al., 2003). The kidney abnormalities 
have been reported in an earlier study, which demonstrates that mouse kidney 
cells mostly depend on nucleotide salvage pathway rather than the de novo 
synthesis (Zaharevitz et al., 1993).  Most of tumour cells had higher TK1 
activity except in kidney cells where TK1 activity was 3 fold higher in normal 
kidney cells compared to renal cell carcinoma cells due to increased de novo 
synthesis (Luo et al., 2009; Luo et al., 2010). A recent study demonstrated that 
TK1 had a potential role in haematopoiesis especially in the maturation of 
lymphocytes (Alegre et al., 2012). TK1 apparently also plays a role in auto 
immune diseases especially leukocytes from patients with Hashimoto and 
Graves’ disease had two fold higher TK1 expression compared to healthy 
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individuals (Karbownik et al., 2003). These results indicate the role of TK1 in 
normal immune system and kidney physiology.  
 
 
4.5  Methods for detection of TK1 
The tight regulation of TK1 during cell cycle and high levels in S phase 
explains why TK1 activity is directly associated with cell proliferation. High 
TK1 activity in rapidly proliferating malignant cells have been demonstrated 
by determining the TK1 levels with different assays. TK1 detection methods 
rely on activity assays and protein based assays (Fig 7) as described below. 
 
 
 
 
Figure 7.  Different TK1 activity and TK1 protein based assays. 
 
 
4.5.1  TK1 activity assays 
 
In the early 1980s, Ellims et al described a method to measure thymidine 
kinase levels in plasma from patients with megaloblastic anaemia. The high 
TK activity levels in megaloblastic anaemia patients compared to normoblastic 
anaemia encouraged measurements of TK levels in other proliferative diseases 
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(Ellims et al., 1980). These initial studies rely on dT phosphorylation methods 
to determine TK activities, similar to those that have been used for many years 
to measure TK activities in cell and tissue extracts. An improvement in 
sensitivity of TK activity determinations was described in 1982 where the viral 
TK activities in herpes simplex virus type 1 and 2 infected cells were measured, 
using [125I]-deoxyuridine as substrate. The reaction products were applied on 
DE-81 filter papers and bound dTMP was measured in a gamma counter 
(Gronowitz & Kallander, 1980). This assay was further developed in order to 
determine the TK activity in sera from patients with Hodgkin’s and non-
Hodgkin’s lymphomas (Gronowitz et al., 1983). The assay was finally validated 
and developed as the commercially available TK-REA assay. The other 
traditional method that was used to measure TK1 activity in serum samples 
from different malignancies is [3H]-dT phosphorylation assay, which is based 
on phosphorylation of [3H]-thymidine to thymidine monophosphate (TMP) by 
using ATP. Similar to previous methods, the [3H]-dTMP was absorbed to ion 
exchange DE-81 filter paper and radioactivity is measured (O'Neill et al., 
1986; Sharif et al., 2012). TK1 only utilizes ATP as phosphate donor whereas 
TK2 utilizes both ATP and CTP, so the relative contribution of TK1 can be 
distinguished by using ATP and CTP separately (O'Neill et al., 1986). 
However, addition of other components to the reaction mixture was 
essential such as reducing agents to ensure consistency in TK1 activity 
levels in different samples (O'Neill, et al., 1986; Sharif et al., 2012).   
 
A non-radiometric assay has been developed during the late 90s, based on the 
substrate analogue AZT instead of labelled thymidine. AZT is phosphorylated 
to AZTMP by TK1 and the amount of AZTMP formed can be determined by 
using polyclonal antibody against AZTMP (Öhrvik et al., 2004; von Euler et 
al., 2009). This assay is commercially available from DiaSorin Inc and is a 
fully automated competitive form of TK activity assay (TK Liaison assay). 
The assay correlates very well with the TK-REA and has similar specificity 
and sensitivity (von Euler et al., 2006; von Euler et al., 2009; Sharif et al., 
2012). One advantage is that it is more specific for TK1 than the TK-REA 
because TK2 present in the samples phosphorylates AZT much less efficiently 
than 125I-dUrd (Munch –Petersen et al., 1991). However, the performance of 
the TK Liaison is to some extent dependent on the properties of the TK1 
enzyme from different species. For example, human TK1 phosphorylates dT 
three times more efficiently than AZT (Eriksson et al., 2002; Sharif et al., 
2012), whereas canine TK1 phosphorylates AZT and dT with similar 
efficiency (Hanan et al., 2012). This indicates that TK-Liaison assay may be 
more suitable for in vitro diagnostics of canine than those of human 
malignancies. Several studies have also shown that the TK-Liaison assay 
works well as a diagnostic tool for canine malignancies (von Euler et al., 
2009; Thamm et al., 2012). There is one potential problem in the TK Liaison 
e.g. interfering endogenous antibodies in human serum which may cross react 
with AZTMP antibodies (Öhrvik et al., 2004). The TK-Liaison assay has been 
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used for tumour management and healthy screening in dogs with apparently 
promising results (Veterinary Diagnostics Institute, VDI, USA). 
 
Another different approach to measure serum TK activity is the DiviTum 
assay, where 5-bromo-deoxyuridine (BrdU) is used as a substrate. TK 
phosphorylates the BrdU to BrdUMP and subsequently to the BrdUTP, which 
is further incorporated into a poly-A oligonucleotide immobilized on the 
bottom of the micro titre plate. Then recombinant reverse transcriptase is used 
with an oligo (dT) primer. The anti-bromodeoxyuridine antibody conjugated 
to alkaline phosphatase is used to measure the poly A/bromodeoxyuridine 
incorporated oligomer which represents the TK1 activity (Nishman et al., 
2013). Both the TK-Liaison and DiviTum assays apparently gave similar 
sensitivity but the DiviTum is a manual assay whereas the TK-Liaison is 
automatic. Other alternative approaches have been described for determining 
TK1 activity in clinical samples, e.g. liquid chromatography-MS/MS through 
phosphorylation of 3-deoxy-3-[18F] flurothymidine (FLT) in hepatocellular 
carcinoma patients which is another thymidine analogue (Faria et al., 2012). 
Alternatively, capillary electrophoresis was used to quantify the amount of 
dTMP formed, following the traditional TK assay procedure instead of DE-81 
filters (Tzeng & Hung, 2005). Recent study has described a new PCR based 
real time assay that measures simultaneously both TK1 and dCK levels in 
clinical samples (Stalhandske et al., 2013). These alternative methods are still 
at an early stage development and only a few clinical studies have been done 
so far.  
 
4.5.2  TK1 protein Assays 
 
Development of antibodies against different regions of TK1 not only 
suggests alternative assays for TK1 activity but also widens the clinical 
applications of TK1 as a biomarker. In the TK1 sequence, the N-terminal is 
conserved among most of the mammals and but not the C-terminal. 
Therefore, most of the clinically useful TK1 antibodies are raised against the 
C-terminal region (Wu et al., 2003) or against the active site lasso loop 
region (Gasppari et al., 2009; von Euler & Eriksson et al., 2011).  In 2001, 
the first study was done with a monoclonal human TK1 antibody, using 
purified cellular TK1 extract as antigen and an ELISA developed with this 
antibody showed correlation with the activity assay. However, this antibody 
ELISA was not developed further until 2014 (Zhang et al., 2001; Alegre et 
al., 2014). Later high affinity polyclonal chicken IgY antibodies were 
developed, which are raised against the C-terminal region of human TK1. 
This antibody is used in dot blot assay to quantify the serum TK1 protein 
levels. The assay is highly sensitive and it can detect the TK1 protein levels 
down to 33 pg/mL (Wu et al., 2003). A commercial dot blot kit, produced by 
SSTK Biotech Inc. was approved by the Supervision Authority for Food and 
Medicine in China for clinical utility in 2010 (Pan et al., 2010). In the past 
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decade, a large number of clinical studies were performed with this assay i.e. 
almost 3,500 different malignant sera and more than 70,000 healthy 
individuals have been tested and reported (He et al., 2005; Li et al., 2005; He 
et al., 2006; Zhang et al., 2006; Chen et al., 2008; Xu et al., 2008; Chen et al., 
2010; He et al., 2010; Li et al., 2010; Chen et al., 2011; Liu et al., 2011). 
Recently, a study using the dot blot assay for health screening of 35,365 
different working individuals found about 1% of individuals had elevated 
serum TK1 protein levels, typically corresponding to individuals with potential 
pre-malignancies (Chen et al., 2011). The main limitation of the dot blot assay 
is that it cannot be directly applied to the existing clinical routine procedures 
and requires specially trained staff and a scanning instrument. Therefore, the 
dot blot method is presently not available outside China. 
Some attempts have been made recently to develop more clinically useful 
antibody assay like a direct ELISA (Alegre et al., 2014) or a sandwich ELISA 
(Carlsson et al., 2009), but in both cases they have not so far been transformed 
to a certified in vitro diagnostic tool. Thus, there is still a need for a robust 
TK1-ELISA assay, adopted to routine clinical practice which can aid disease 
management of different malignancies. To determine the performance of any 
diagnostic test that differentiates a group with disease from a group without 
disease, receiver operating characteristic (ROC) curves are used. Basically the 
ROC curve is a plot of true positive rates against a function of false positive 
rates at a series of different cut-off points. The main statistics associated with 
ROC curve are i.e. the area under the curve (AUC), the sensitivity and the 
specificity. The AUC in ROC curve quantifies the overall ability of the test to 
discriminate the disease group from the non-disease group. Sensitivity 
represents the fraction of positives in test population that can be identified as 
true positives by the diagnostic test and the specificity indicates the fractions 
of negatives in test population that are true negatives. In later sections of this 
thesis, ROC curve analysis for different TK1 assay results was used to 
determine the sensitivity and specificity values as well as the AUC, giving a 
quantitative estimation on quality of the various tests. 
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5. TK1 in human and veterinary medicine 
 
5.1  TK1 determinations in human medicine 
 
In many haematological tumours, serum TK1 (STK1) activity levels are 
significantly elevated especially in acute lymphoblastic leukemia (ALL), acute 
myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), Hodgkin’s 
lymphoma (HL), non-Hodgkin’s lymphoma (NHL), myelodysplastic syndrome 
(MDS), and multiple myeloma (MM).  
Significantly elevated levels of STK1 were found in ALL patients compared to 
healthy controls (Hagberg et al., 1984; O Neil et al., 2007) and the levels of 
STK1 depends on stage of disease, and in the case of pre-treatment and 
relapsed patients, high STK1 activities are a sign of tumour progression. In 
patients with complete remission, no significant difference was observed in 
STK1 activity compared to healthy individuals (O Neil et al., 2007). Moreover, 
TK1 activity levels fluctuated in response to treatments, indicating that STK1 
is suitable in disease monitoring. In both ALL and AML patients, serum TK1 
activity levels are elevated early after treatment, but decrease after 2-4 weeks 
and stay at low levels during remission. However, increase in STK1 activity 
was observed in patients with relapse of tumour disease (O Neil et al., 2007). A 
similar study in children with acute leukemia (34 lymphocytic, 4 myeloblastic) 
showed high TK1 activity levels at the time of diagnosis, which decreases 
during therapy and reaches to levels similar as healthy individuals. In relapsed 
patients, STK1 levels started to increase 1 month before clinical symptoms 
were detected (Votava et al., 2007).  
In CLL patients, STK1 levels correlated with prognosis i.e. overall survival 
and the STK1 levels could also aid in distinguishing smoldering and non-
smoldering disease as well as predicting progression-free survival (PFS). 
Patients with high TK1 (> 7.1 U/L) had an average PFS of 8 months and for 
patients with low TK1 (< 7.1 U/L) PFS was 48 months. These results 
demonstrated the prognostic capacity of STK1 (Hallek et al., 1999). In another 
study with 188 advanced CLL patients, the STK1 levels before treatment could 
identify the patients that were most likely to respond to treatment. This study 
showed that almost all CLL patients had higher levels of STK1 before 
treatment than after treatment with Fludarabine. Overall, 83% of the CLL 
42 
patients with low STK1 levels (< 10 U/L) responded to Fludarabine with a 
median survival rate of 65%. On the other hand, 45% of the patients with high 
STK1 levels (> 10 U/L) showed low response to the treatment and a median 
survival rate of 22% (Di Raimondo et al., 2001). A recent study in CLL 
patients also demonstrated the prognostic value of STK1 (Konoplev et al., 
2010). In the CLL patients, immunoglobulin heavy chain (IgvH) mutations are 
common, and tests to distinguish mutated IgvH from unmutated IgvH, markers 
like Zap 70 and CD 38, are often used. A recent study demonstrated the 
relation between STK1 levels and these markers. Elevated STK1 levels were 
found in patients with high expression of Zap 70 and CD 38 as well as the 
stage of disease. Furthermore, STK1 showed significant correlation with white 
blood cell counts and absolute B-cell counts (Rivikina et al., 2011; Szantho et 
al., 2014). 
Several studies have demonstrated the prognostic and diagnostic value of 
STK1 in NHL (Gronowitz et al., 1983; Hallek et al., 1992). STK1 levels in 
pre-treatment patients were related to the grade of malignancy (low, medium 
and high) and provided information regarding response to treatment, and 
predicted overall survival (Hagberg et al., 1984; Hallek et al., 1992). In some 
cases, STK1 helped to predict the transition of disease from indolent to 
progressive before the symptoms appear (Hallek et al., 1990). STK1 had higher 
capacity to predict the course of disease in NHL patients compared to other 
serum markers like β2-macroglobulin, lactic dehydrogenase and haptoglobin 
(Gronowitz et al., 1983; Hagberg et al., 1984). 
In HL, STK1 levels in pre-treated patients correlated with clinical parameters 
such as cancer stage and histopathology (Eriksson et al., 1985). High STK1 
levels corresponded to an advanced stage of disease. Further, STK1 levels 
could discriminate IA and IIA stages of HL into subgroups based on disease 
free survival (Eriksson et al., 1985; Hallek et al., 1992). 
STK1 levels predicted also the transformation of MDS to AML and 
multivariate analysis showed that STK1 is the only prognostic marker that 
provides information about acute transformation potential, response to therapy 
and overall survival (OS) (Musto et al., 1995). Moreover, MDS patients with 
STK1 activity higher than 38 U/L had shorter survival times compared to 
patients with low STK1 level (< 38 U/L) (Musto et al., 1995). STK1 could also 
distinguish MM from monoclonal gammapathy of undetermined significance 
(MGUS), where patients with MGUS had significantly lower STK1 levels 
compared to MM. STK1 levels in MM increased in relation to the disease 
progression and high pre-treatment STK1 levels strongly associated with short 
survival (Brown et al., 1989; Back et al., 1993). 
The prognostic relevance of STK1 was investigated in various solid tumours 
such as breast, lung, and bladder, ovarian, gastrointestinal and prostate cancers. 
Breast cancer has been studied extensively; TK1 activity levels were measured 
in cytosolic TK1 extraction from tumour tissues of approximately 1700 
primary breast cancer patients. TK1 activity correlated with disease-specific 
survival (DSS), local recurrence-free survival and distant relapse-free survival. 
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It also could monitor the effectiveness of the chemotherapy (Broet et al., 2001). 
Another study showed significantly higher STK1 levels in 160 breast cancer 
(BC) sera compared to sera from healthy women. This study concluded that 
increases in STK1 levels were associated with staging, grade and vascular 
invasion. Further, elevated STK1 levels were found in patients with BRCA 1 
or BRCA 2 mutations compared to those without mutations and STK1 can be 
an independent prognostic factor for recurrence free survival (RFS) (Nisman et 
al., 2010). Recently, another study on breast cancer patients compared the 
performance of the two commercial assays i.e., the TK-Liaison and DiviTum 
assays. Despite some differences between the two assays, the study found 
similar sensitivities and specificities, could predict tumour reoccurrence and 
showed significant correlation (r =0.85) (Nisman et al., 2013). 
Some studies demonstrated the clinical significance of STK1 activity in non-
small cell lung cancer (NSCLC). A recent study on the prognostic significance 
of STK1 in NSCLC found that STK1 activity levels in NSCLC patients are 
significantly higher than in healthy controls. STK1 levels were also correlated 
with weight loss and higher STK1 values were associated with decreased PFS 
and OS. These findings indicate that STK1 can be an independent prognostic 
factor, but it could not be used for monitoring response to therapy in the case 
of NSCLC patients (Korkmaz et al., 2013). 
In ovarian cancer, STK1 levels were found to differentiate patients with high 
stage disease from healthy individuals. Moreover, STK1 levels correlated 
strongly with CA-125, which is a widely used marker for prognosis and 
disease monitoring in ovarian cancer (Hallek et al., 1997). Similarly, STK1 
activity was significantly higher in renal cell carcinoma (RCC) patients and it 
correlated with clinical stage but not with grade. However, STK1 levels could 
not differentiate samples from patients with benign kidney tumours from the 
healthy controls. Overall, high levels of STK1 and TuM2-PK correlated with 
reduced RFS (Nisman et al., 2010). In prostate cancer, STK1 activity levels 
(N=92) were also markedly elevated compared to healthy individuals and 
STK1 activity appeared to be a better marker than PSA in this study (Letocha 
et al., 1996). 
Development of TK1 antibodies provides an alternative approach to the 
traditional activity assays as described above. Most of these antibodies were 
developed against the C-terminal region of human TK1 and originally with a 
16-mer peptide as antigen (He et al., 1996).  A similar type of antibodies using 
a (31-mer) 31 C-terminal peptide for immunization of chickens lead to 
development of the commercial dot blot assay (Wu et al., 2003). With the dot 
blot assay, STK1 protein (STK1p) levels in patients with benign and malignant 
breast cancer were determined, and significantly higher STK1p were evident in 
pre-operative patients compared to 3 months after surgery. Patients with 
metastatic disease had significantly higher STK1p compared to patients with 
no metastasis. In healthy individuals, STK1p levels were significantly lower as 
compared to benign and malignant breast cancer patients (He et al., 2000). In 
another study, CA 15-3 (a breast cancer marker) and STK1p levels were 
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compared in pre-operative breast cancer patients and 3 months after surgery. 
STK1p levels increased in patients with recurring disease but this was not 
clearly seen with CA15-3, indicating that STK1p could be a better marker for 
early detection of breast cancer recurrence than CA 15-3 (He et al., 2006). In a 
recent study, STK1p levels were determined in the follow up of 51 patients 
after surgery and chemotherapy for 44 months. Patients with high STK1p (≥ 
2.0 pM) levels 3-6 months after surgery had higher clinical stage, grade and 
larger tumour size. Furthermore, patients with high STK1p exhibited 11-12 
times higher risk for development of metastatic disease compared to those 
with low STK1p values. Moreover, patients in stage III/IV with low STK1p 
levels showed significantly improved survival compared to the patients with 
high STK1p levels (Chen et al., 2013).  
Studies have been conducted with the dot blot assay in patients with other 
different solid tumours such as bladder carcinoma (Zhang et al., 2006), 
gastrointestinal cancer (Zou et al., 2002), renal cell carcinoma (Luo et al., 
2009), cervical cancer (Fujiwaki et al., 2001), ovarian cancer (Fujiwaki et al., 
2002) and prostate cancer (Li et al., 2011), and they all suggest that STK1p 
can play a major role in the management of malignant diseases. The dot blot 
assay has also been extensively used for health screening in China; the initial 
test was conducted in 2006 with 72 individuals found that 3 individuals had 
elevated STK1p levels (1.8, 7 and 7.1 pM) compared to healthy individuals 
(0.5 pM). The persons with high STK1p had some proliferation related 
abnormalities as revealed in the clinical examinations (Chen et al., 2008; He 
et al., 2010). Based on these preliminary results, a larger health screening 
study has been conducted with 35,000 people from different regions in China. 
About 0.8% of the individuals had elevated STK1p and of these about 85% 
had diseases associated with cell proliferation or sometimes with established 
malignancies compared to individuals with low STK1p values (0.5 pM) (Chen 
et al., 2011). 
Another antibody based sandwich ELISA was developed AroCell AB, and a 
preliminary study was conducted with breast carcinoma patients subsequent to 
surgery (N =24) and chemotherapy (N=39). Although STK1p values were 
significantly reduced 4 weeks after surgery and increased in patients after 
tumour recurrence, this ELISA had surprisingly low sensitivity and specificity 
(Carlsson et al., 2009). Recently, another study was conducted with a new form 
of the TK1- ELISA, based on two monoclonal antibodies by AroCell AB. In 
this study, breast cancer patients were divided based on TNM classification. 
Elevated TK1 protein levels were found in  breast cancer patients compared to 
healthy patients, and TK1 protein levels differed significantly between groups 
based on size (T1<T2<T3). Furthermore, STK1p levels correlated significantly 
with CA 15-3, this study concludes that STK1p can detect early stages of 
breast cancer more efficiently but not CA15-3 (www.arocell.se).  
In another study with lung carcinoma patients conducted by Alegre et al, the 
STK1p levels were determined in stage I (N=16), stage II (N=17) patients as 
well as in healthy controls (N=18) by a direct ELISA. The patients with stage I 
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and stage II showed significantly higher STK1p levels compared to healthy, 
whereas STK1activity levels only differentiated stage II from healthy but not 
stage I. These results indicate that STK1p was a more sensitive indicator for 
lung cancer compared to STK1 activity (Alegre et al., 2014). However, the 
levels of STK1p determined in this study was about 100 fold higher than those 
found with the dot blot assay or the AroCell ELISA, so further studies are 
needed to clarify these discrepancies. Results with another form of TK1-
ELISA were conducted and compared with the CA15-3 and CEA (another 
tumour marker) of breast cancer patients. The percentage of breast cancer 
patients with high levels of CEA, CA15-3 and STK1p were found to be 62%, 
70% and 78%, respectively. It was also demonstrated that combination of 
these three markers increased the sensitivity to 90% for accurate diagnosis in 
breast cancer patients (Elfagieh et al., 2012). However, the details of the 
antibodies used in this assay were not described and no further studies with 
this assay have been reported.  
TK1 antibodies have been used in a number of immunohistochemistry (IHC) 
studies to determine the TK1 expression in tissues and compared with other 
proliferation markers such as PCNA and Ki-67. TK1 and PCNA were both 
overexpressed in malignant tissues compared to normal tissues but only TK1 
expression significantly increased with grade and stage in breast, liver, lung, 
colon, kidney, prostate, thyroid and stomach cancer tissue samples (Wu et al., 
2000; Mao et al., 2002; Wu et al., 2003; Mao et al., 2005; Alegre et al., 2012). 
TK1 expression showed a strong positive correlation with Ki-67 expression in 
breast atypical ductal hyperplasia (ADH), infiltrating ductal breast carcinoma 
(IDC) and in NSCLC (He et al., 2004; Brockenbrough et al., 2009; Guan et al., 
2009). TK1 expression in breast cancer tissues was also examined in order to 
identify the pre- malignant diseases. For ADH, IDC, ductal carcinoma in-situ 
(DCIS) and usual ductal hyperplasia (UDH), the TK1 positive rates are 
significantly increased in the following order: UDH<ADH<DCIS<IDC. TK1 
expression also correlated with histological grade and pathological stage. 
These IHC results strongly suggest that TK1 is a promising proliferation 
marker for pre-cancer as well as different forms of malignant breast cancer 
(Guan et al., 2009). TK1 expression was also compared with Ki-67 expression 
in cell cycle studies with Array Scan analysis. The results showed that TK1 
starts to increase earlier than Ki-67 after stimulation of growth arrested normal 
human fibroblasts (Gasparri et al., 2009). Expression of TK1 and Ki-67 were 
also examined in ovarian adenocarcinoma and the expressions of both these 
markers correlated with pathological stage, tumour size and grade. Further 
analysis showed that patients with advanced disease and low TK1 expression 
had better survival compared to patients with high TK1 expression (Liu et al., 
2011). 
In a recent study, TK1 expression was investigated in prostate cancer patient 
samples (N=103) and compared to the Gleason scores and prostate specific 
antigen (PSA) levels in the same patients. TK1expression was significantly 
higher in prostate tissues compared to normal tissues and TK1 expression 
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correlated with the Gleason score and disease staging. It was concluded that 
TK1 expression not only differentiated tumour tissues from normal tissue but 
also provided predictive information concerning biochemical relapse and onset 
of metastatic disease (Aufderklamm et al., 2012). 
In summary, both STK1 activity and STK1p levels could give information 
related to survival, recurrence and response to treatment. For pT1 lung 
adenocarcinoma patients, high TK1 expression is significantly associated with 
worse 5-year survival (Xu et al., 2012). In addition, TK1 expression was able 
to identify the node-negative breast cancer patients that were at a high risk for 
metastasis (Romain et al., 2001). Studies reported that TK1 activity from tissue 
extract is 12-fold higher in ovarian carcinoma, and 2-fold higher in bladder 
carcinoma compared to normal controls. Finally, it was also shown that 
carcinomas with low tissue TK1 activity had longer RFS (Demeter et al., 2001; 
Mizutani et al., 2002). 
Serum TK1 determinations and TK1 expressions are often combined or 
compared with imaging techniques like Positron Emission Tomography (PET), 
which utilizes labelled thymidine analogues. PET can provides valuable 
information regarding tumour size and localization, and the aggressiveness, 
and response to treatment of various human cancers such as breast, lung, head 
& neck cancer, gliomas as well as lymphomas (Buck et al., 2007; Salskov et 
al., 2007; Herrmann et al., 2011; Richard et al., 2011). Similarly, some studies 
were done with PET for monitoring FLT uptake in relation to TK1 and Ki-67 
expressions, and it was found that low FLT uptake was surprisingly associated 
with high TK1/Ki-67 expression (Zhang et al., 2012). Another study reported 
that FLT uptake is strongly correlated with TK1/Ki-67 IHC expression but not 
with tissue TK1 activity (Brockenbrough et al., 2011). However, other studies 
showed that FLT uptake correlates with TK1 expression as well as with tissue 
TK1 activity (Rasey et al., 2002; Barthel et al., 2005; Kameyama et al., 2011). 
These controversies has been further expanded since a recent study concluded 
the FLT uptake and retention could not be used to measure tumour cell 
proliferation rates because FLT phosphorylation did not correspond to TK1 
expression or tissue TK1 mRNA levels (Shinomiya et al., 2013). Thus, the 
relation between TK1 expression and FLT uptake in tumour cells is still 
unclear. 
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5.2  TK1 determinations in veterinary medicine 
 
The first study describing TK1 determinations in dogs was done in 1997 by 
Nakamura and colleagues. They reported that plasma TK1 activities in dogs 
with lymphoma and leukemia (N=20) were significantly higher compared to 
clinically healthy dogs (N=13). The plasma TK1 activity values in dogs with 
lymphoma decreased in parallel with the reduction of tumour mass after 
treatment, whereas two dogs with tumour relapse showed increased plasma 
TK1 activity levels. Furthermore, plasma TK1 activities in sera from dogs with 
lymphoma and leukemia dogs were compared with the lactate dehydrogenase 
(LDH) levels, and a significant correlation was found (r = 0.64). Moreover, 
plasma LDH activity was neither as sensitive nor as specific as the TK1 
activities (Nakamura et al., 1997). The second study by von Euler et al on dogs 
with malignant lymphoma was designed to determine the prognostic capacity 
of the STK1. STK1 activity in dogs with lymphoma (n=52) was significantly 
higher compared to healthy dogs. Following treatment, STK1 activity was 
determined in 44 dogs at regular intervals and no significant differences were 
found between the mean STK1 activities of dogs with complete remission 
(CR) and healthy dogs. Furthermore, dogs with high STK1 levels (> 30 U/L) 
had shorter OS (1.5 months) compared to dogs with low STK1 levels (< 
30U/L) having a median survival of 9 months. Finally, increased STK1 levels 
could predict the relapse 3 weeks before onset of clinical symptoms (von Euler 
et al., 2004). 
Further studies on STK1 were done using the TK-Liaison assay (von Euler et 
al., 2006; von Euler et al., 2009) in large groups of dogs with malignant 
lymphoma (N=213) and leukemia (N=35). It was concluded that STK1 activity 
levels in dogs (N=56) with complete remission (0.5-7.0 U/L) were similar to 
healthy dogs, whereas dogs (N=28) with progressive disease had significantly 
higher STK1 levels (7-66 U/L). Dogs with leukemia had highest STK1 activity 
(30-263 U/L) and STK1 levels in dogs under remission after chemotherapy 
were reduced compared to the initial TK1 levels. These studies demonstrate the 
prognostic potential of STK1 and its value for response monitoring after 
treatment of dogs with malignant lymphoma. Furthermore, the non-radioactive 
TK-Liaison assay gave results similar to TK-REA and the correlation between 
the two assays was excellent (r = 0.97).  
In a separate study, STK1 levels were determined in 73 dogs with lymphoma 
and 46 out of 73 dogs were also immune-phenotyped. Overall, 47% of the dogs 
with lymphoma showed TK1 levels higher than the normal reference range.  
Dogs with naive B-cell lymphoma had significantly higher TK1 activity levels 
than dogs with naive T-cell lymphoma. There was no association between 
STK1 activity and clinical stage of disease. However, dogs with high STK1 
levels were in the normal range during remission (Elliott et al., 2011). 
A recent study was done on STK1 activity in dogs with malignant lymphoma 
(ML) by an optimized [3H]-dT phosphorylation assay. The performance of 
assay was compared with the commercially established TK1 enzyme assays 
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such as TK-REA and TK-Liaison. STK1 activity was assayed in 29 dogs with 
ML and STK1 activity was significantly higher in sera from dogs with ML 
compared to healthy dogs. ROC curve analysis showed that the assay had a 
sensitivity of 0.94 and a specificity of 0.68. There was a significant correlation 
between [3H]-dT phosphorylation assay with other TK activity assays such as 
TK-REA (r=0.92) and TK-Liaison assays (r=0.96, p<0.0001) (Sharif et al., 
2012). 
The above mentioned studies also included samples from dogs with solid 
tumours, i.e. STK1 activity levels were determined in sera from 4 dogs with 
solid tumours by Nakamura et al (1997), 50 dogs with solid tumours in the 
study by von Euler et al (2009) and in 35 solid tumour dogs by Sharif et al 
(2012). Surprisingly, the STK1 levels were below the normal reference range 
in the first study, and 3 out of the 50 dogs with solid tumours had high STK1 
levels in von Euler et al., (2009). Similarly, in the study by Sharif et al (2012) 
4 out of 35 had higher STK1 levels compared to the cut-off value from 
healthy dogs. The conclusion was that the STK1 activities in dogs with solid 
tumours differ significantly from those in healthy dogs only in very few cases 
and therefore STK1 activity measurements are not useful clinically with these 
patients. 
Another study on the STK1 levels in dogs with hemangiosarcoma (HSA),  
demonstrated significantly higher STK1 activities in sera from HSA patients 
compared to those in healthy dogs, but not in dogs with benign disease. Still, 
the ROC analysis demonstrated only a sensitivity of 0.52 and specificity of 
0.93 for the patient groups with HSA compared to the healthy groups. Patients 
with other solid tumours were also tested and only 6.7% of osteosarcoma and 
11% of transitional cell carcinoma had increased STK1 levels. These results 
suggest that STK1 can be a marker for differentiating between benign disease 
and HSA (Thamm et al., 2011). STK1 activity has also been tested along with 
canine CRP in healthy screening projects for dogs and this combination could 
be used to predict the onset of tumour disease. A study with 360 dogs was 
done for 6 months and both STK1 activity and CRP levels were determined at 
regular intervals. Both the STK1 and CRP concentrations were higher in dogs 
with cancer compared to healthy dogs. In addition, ROC curve analysis based 
on STK1 activity 6 months prior to the onset of cancer disease, showed a 
sensitivity of 0.73 and a specificity of 0.84. A Neoplastic Index (NI) was 
constructed, which used both STK1 and CRP levels, and this index showed 
higher sensitivity compared to each marker alone. The conclusion from this 
study was that serum TK1 can be used to predict early stages of cancer 
whereas NI can predict onset of cancer more efficiently (Selting et al., 2013).  
The first study of STK1 activity levels in feline lymphoma was recently 
published. The study included cats with lymphoma (N=33), inflammatory 
diseases (N=55), non-hematopoietic neoplasia (NHPN) (N=34) as well as 
clinically healthy cats (N=49). Cats with lymphoma had significantly higher 
mean STK1 activity (17.5 U/L) than healthy cats (2.2 U/L) or cats with 
inflammatory disease (3.4 U/L) and cats with NHPN (4.2 U/L). These results 
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indicate that STK1 could be a biomarker for feline lymphoma (Taylor et al., 
2012). Another recent study was published on clinical significance of STK1 
activity in equine lymphomas. STK1 activity was measured by TK-REA in 
healthy horses (N=37), lymphoma horses (N=23) along with few samples 
from other infections also. STK1 activity was significantly higher in horses 
with lymphomas compared from healthy horses. The results suggested that 
STK1 can be a potential biomarker in equine lymphomas (Larsdotter et al., 
2015). Both these studies on clinical use of STK1 activity in cats and equines 
are preliminary, but the prognostic role of STK1 in tumour management is 
still unclear. 
 
5.3  TK1 determinations in non-neoplastic diseases 
 
Serum TK activity levels are elevated in some viral infections such as 
cytomegalovirus (CMV), varicella-zoster virus (VZV), Epstein-Barr virus and 
herpes simplex virus (HSV) (Gronowitz et al., 1982; Kallander et al., 1982; 
Gronowitz et al., 1984; Gronowitz et al., 1986; Kallander et al., 1989). Even 
though patients with acute hepatitis showed high STK1 levels, only hepatitis- 
A patient had the highest STK1 activity (Tanaka et al., 1993). The increase in 
STK1 could be due to virus encoded TK released during the infection 
(Gronowitz & Kallander 1983) or TK1 originating from damaged host cells 
(Tanaka et al., 1993). STK1activity also increased significantly in patients 
with vitamin B12 deficiency and this is most likely because of interference in 
de novo pathway due to vitamin B12 deficiency which causes the leakage of 
TK1 from immature proliferating blood cells as described earlier. The STK1 
levels normalize rapidly after vitamin B12 supplement therapy (Hagberg et al., 
1984; Ellims et al., 1980; Hooton & Hoffbrand et al., 1976). 
Some early studies on dogs with bacterial infection and unspecified 
inflammatory diseases have been done and the STK1 activity levels were 
within the normal reference range (Nakamura et al., 1997; von Euler et al., 
2009). However, a study of 54 dogs with pyometra showed that STK1 levels 
were significantly increased in a subset of these dogs. The other finding was 
that 6 out of 10 dogs with pyometra had significant reduction in STK1 activity 
after ovariohysterectomy. Furthermore, toxic neutrophils and monocytes 
counts showed a trend towards being correlated with the STK1 activities, 
indicating that the increase in STK1 activity could be associated with the 
severity of infection (Sharif et al., 2013).  
The STK1 activity levels in bovine leukosis (BL) were found to be increased, 
most likely associated with the leukocytosis. Of 20 cows with bovine leucosis 
virus infection 19 had significantly higher STK1 activities compared to 
healthy cows, whereas 7 out of 79 cows with other diseases had elevated 
STK1 levels. In ROC curve analysis, the sensitivity and specificity of STK1 
for diagnosis of bovine leukosis was 95% and 95.9%, respectively (Sakamoto 
et al., 2009). In another study, STK1 activity was demonstrated to be a useful 
as diagnostic tool for BL with difficult diagnosis and clinically confirmed BL. 
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High STK1 activity was found in 84% of cows with difficult diagnosis of BL 
and 97% in cows with confirmed BL, whereas in cows with other tumours and 
inflammatory diseases the sensitivities were 15 and 21%, respectively 
(Tawfeeq et al., 2013). Thus, it seems possible that STK1 measurements could 
be a valuable tool also in ruminant medicine. 
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6. Aims of the thesis 
 
The main aim of these studies is to widen the clinical utility of TK1 as a 
biomarker in veterinary medicine. Specific attention was given to an antibody 
based assay that can determine the serum TK1 protein levels in different canine 
malignancies. These antibody based assays provides better understanding about 
the molecular forms of serum TK1 in canine lymphomas and mammary 
tumours. This information will help to improve the clinical use of TK1 activity 
TK1 protein assays for in vitro diagnostic procedures in canine oncology and 
in comparative medicine. 
 
The following specific aims were set: 
 
Ø To determine the TK1 26 kDa protein levels in sera from dogs with 
malignant diseases by using an antibody based immunoaffinity assay. 
Furthermore, to evaluate the TK1 antibody assay in comparison with 
[3H]-dT phosphorylation assay for experimental and clinical purposes. 
Ø To determine the effect of reducing agent on TK1 activity and TK1 
peptide antibody performance in the immunoaffinity assay. 
Ø To study the molecular forms of human, dog recombinant TK1 and 
compare them with the cellular and serum forms of TK1 from humans 
and dogs. Further to determine the enzyme behavior in presence of 
reducing agents.  
Ø To assess the possibility of using STK1 protein levels as a biomarker 
in dogs with mammary tumours. To determine the differences in the 
molecular forms of cellular and serum TK1 in canine acute 
lymphocytic leukemia and canine mammary tumours. 
Ø To develop a sandwich TK1-ELISA and evaluate its performance in 
comparison with [3H]-dT phosphorylation assay in different canine 
malignancies. 
Ø To make a preliminary assessment on clinical performance of the new 
TK-ELISA in dogs with lymphomas and solid tumours. 
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7.  Main results and discussion 
 
A detailed discussion of each specific study is given in the respective papers. 
In the general discussion below, the main results and conclusions of the 
investigations are summarized. For further details, see Papers I-IV. 
 
7.1. Paper I 
 
High levels of inactive thymidine kinase 1 polypeptide detected in sera 
from dogs with solid tumours by immunoaffinity methods: Implications 
for in vitro diagnostics. 
 
This study concerns about the relation between serum TK activity and TK1 
protein in sera from dogs with different malignancies and healthy dogs. A new 
TK1 antibody based assay is described and used to determine TK1 polypeptide 
levels in dogs with haematological neoplasia (lymphomas and leukemia) as 
well as solid tumours. The effect of a reducing agent (DTE) on serum TK1 
binding to an anti TK1 peptide antibody Sepherose was also studied. 
Determinations of STK1 activity levels had so far relied on TK-REA, TK-
Liaison and [3H]-dT phosphorylation assays. These assays demonstrated that 
dogs with haematological tumours have significantly higher levels of TK1 
compared to healthy dogs but this was not seen in sera from dogs with solid 
tumours (Sharif et al., 2012; von Euler et al., 2009; Nakamura et al., 1997). 
This clearly limits the clinical use of STK1 as a diagnostic tool in veterinary 
medicine. 
Development of antibody based assays for TK1 protein in human medicine 
inspired the approach used here to establish an immunoaffinity assay for canine 
TK1 protein (Wu et al., 2003; He et al., 2005). The TK1 26 kDa protein was 
measured by reacting serum samples or recombinant dog TK1 with an anti 
TK1 peptide antibody Sepharose, followed by a washing procedures and 
elution of the bound proteins. They were then analysed by western blot using a 
polyclonal anti TK1 antibody for detection of the dog TK1 sub unit of 26 kDa 
protein (Fig 8). The band intensities were measured by densitometry and the 
corresponding protein levels were determined with different concentrations of 
recombinant dog TK1 as standard. The study comprised 47 samples from dogs 
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with different malignancies. i.e., leukemia (n=3), lymphoma (n=5), solid 
tumours (n=21) as well as healthy dogs (n=18). 
 
Figure 8. Isolation of TK1 polypeptide from dog serum samples by immunoaffinity 
assay. 
 
The TK1 26 kDa polypeptide was quantified in sera from dogs with 
hematologic malignancies, solid tumours and healthy dogs in parallel with 
STK1 activity measurements. The results are shown in Table 2. 
 
Table 2. Summary of serum TK1 activity and TK1 protein levels in dogs. 
Tumour type     N    STK1 protein (ng/mL)   STK1 activity  (pmol/min/mL) 
  
Range Mean Median      Range Mean Median 
Without DTE 
       Leukaemia and lymphoma     8  15 - 47  33   37     16 -255  65    38 
Solid tumours   21  13 - 60  30   31    0.6 - 2.9  1.1      1 
Healthy   18    5 - 18  10     8    0.3 - 1.6  1      1 
        DTE pre-incubation 
       Leukaemia and lymphoma     8  10 - 30  28     27       6 - 282   60     32 
Solid tumours   21    6 - 35  17     14      0.2 - 1.5   0.7    0.7 
Healthy   18    3 - 14    7       6      0.2 - 1.1   0.7    0.7 
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The STK1 activity levels from dogs with haematological tumours were 40 fold 
higher than TK1 activity in sera from dogs with solid tumours. However, the 
mean serum TK1 protein levels in these two cases did not differ significantly 
(33, 30 ng/mL, Table 2).  
Furthermore, there was no significant difference in STK1 activity between 
dogs with solid tumours and healthy dogs in accordance with previous results 
(von Euler et al., 2009; Sharif et al., 2012). However, the STK1 protein levels 
were significantly different in healthy dogs compared to those found in patients 
with solid tumours. There was a significant correlation between STK1 activity 
and TK1 protein levels in sera from dogs with solid tumour sera (rs = 0.51. P = 
0.01), but no correlation was observed for the haematological tumours. This 
may be due to the small number of samples tested. Pre-incubation of serum 
samples with the reducing agent (DTE) gave significant reduction in both the 
STK1 activity and protein levels in all sera, except in the leukemia patient H3, 
where both STK1 activity and protein levels increased after treatment.  
The immunoaffinity assay had good accuracy with patient samples from dogs 
with haematological tumours and solid tumours. ROC curve analysis showed 
an area under curve of more than 90%. Overall the assay showed high 
sensitivity of 72% compared to activity assay with only 44%. The specificity of 
the immunoassay was 94% similar to TK1 activity assay. Thus, the TK1 
protein assay has higher sensitive compared to the TK1 activity assay. The 
specific activity of serum TK1 was subsequently determined based on the 
median STK1 activity and protein values, i.e. nmol [3H]-deoxythymidine 
monophosphate dTMP)/min/mg of TK1 protein. The results showed that the 
TK1 in haematological malignancies had about 30-fold higher specific activity 
compared to healthy dogs. In contrast, the TK1 in healthy dogs showed 2.5-
fold higher specific activity compared to dogs with solid tumours. These 
results indicate that there is a large fraction of inactive TK1 in sera particularly 
in dogs with solid tumours. Further studies are needed to determine the 
diagnostic value of the TK1 protein assay in canine oncology. 
 
Summary (Paper I) 
 
Ø An antibody based assay is described, which showed that TK1 protein 
levels are significantly higher in dogs with solid tumours compared to 
healthy dogs. 
Ø STK1 activity levels in sera from dogs with solid tumours did not 
differ from those in healthy dogs (P = 0.63). 
Ø ROC curve analysis demonstrated that the TK1 protein assay was as 
sensitive as the TK1 activity assay for discrimination of healthy dogs 
from those with haematological tumours. 
Ø ROC curve analysis of serum TK1 protein assay showed 3-fold higher 
sensitivity compared to the TK1 activity assay for dogs with solid 
tumours. 
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Ø The specific activity determination based on TK1 activity and TK1 
protein levels demonstrated that sera from healthy dogs and dogs with 
haematological tumours had significantly higher specific activity 
compared to dogs with solid tumours. 
 
7.2. Paper II 
 
Quaternary structure of recombinant, cellular and serum forms of 
thymidine kinase 1 in dogs and humans 
 
In this study, the molecular forms of cellular, serum TK1 were studied and 
compared with recombinant TK1. Differences in molecular forms of 
recombinant, cellular and serum TK1 between humans and dogs were studied 
by size exclusion chromatography. Human and dog recombinant TK1 were 
cloned and expressed in E. coli and further tested for their substrate 
specificities, thermal stabilities and the effects of reducing agents. The 
substrate specificity of human and dog recombinant TK1 was investigated with 
different concentrations of the AZT and the dT. AZT phosphorylation 
efficiency was 3-fold higher for dog TK1 compared to human TK1. These 
enzymes showed positive co-operativity with dT and AZT with Hill 
coefficients of 1.3 and 1.4, respectively. Dog TK1 was somewhat thermally 
more stable than human TK1. Pre-incubation of recombinant enzymes with 
different concentrations of DTE (0. 2 and 20 mM) on ice for 30 min did not 
significantly effect enzyme activities. However, at higher concentration of 
DTE (100 mM) both the enzymes lost around 50 % of their activity. 
The subunit composition of recombinant, cellular and serum TK1 from humans 
and dogs were determined by size exclusion chromatography. In the case of 
dog recombinant TK1, total recovery was low in the absence of DTE so that 
we could not determine the subunit composition. However, when the enzyme 
was pre-incubated with DTE, recombinant dog TK1 was in high MW 
oligomers and both TK1 activity and TK1 28 kDa protein followed the same 
elution pattern. Human recombinant TK1 behaved in a different manner. It 
eluted as two peaks: a major peak between 720-300 kDa and minor peak 
between 200-50 kDa in absence of DTE. However, pre-incubation of human 
TK1 with DTE shifted the major peak towards the minor peak and in both 
cases, TK1 activity and TK1 subunit of 25 kDa followed a similar pattern. 
These results differ from a previous study, where human TK1 was a dimer in 
the absence of ATP and a tetramer in presence of ATP (Munch- Petersen., 
2009). However, these experiments were performed with lower recombinant 
protein concentrations and in the presence of reducing agents. Cellular TK1 
both from dog and human cells eluted mainly as tetramers, and pre- incubation 
with DTE inhibited dog TK1 activity and had little effect on human TK1 
activity. 
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Serum samples from human and dog patients with acute lymphoid leukemia 
were also analysed by size-exclusion chromatography. In case of the dog 
patient, serum TK1 activity eluted as a single large peak with a MW range of 
720-300 kDa. Western blot analysis demonstrated a TK1 polypeptide in the 
same MW range but there was no direct correlation between TK1 activity and 
TK1 protein in these fractions. Pre-incubation of dog sera with DTE had 
reduced both serum TK1 activity and TK1 protein significantly. There was no 
shift in dog TK1 activity peak whereas western blot demonstrated a minor peak 
in the low molecular weight region. However for human TK1, the activity 
eluted as two peaks: a major fraction in the MW range of 720-300 kDa similar 
to dog serum TK1 and a minor peak in the MW range of 200-50 kDa. These 
results were similar to what was observed in a previous study, which 
demonstrated serum TK1 in oligomeric forms (Karlstrom et al., 1990). Western 
blot analysis showed TK1 polypeptide of 25 kDa in two peaks with more 
intense bands in the low MW region. Pre-incubation with DTE significantly 
shifted the major activity peak to the minor peak region and no TK1 
polypeptide of 25 kDa bands was detected in western blot analysis. 
Human and dog recombinant TK1 showed different quaternary structure as the 
quaternary structure of serum TK1. Furthermore, human and dog serum TK1 
behave differently in presence of reducing agents. This could be due to that 
human TK1 contains more cysteines (11 cysteines-human & 8 cysteines-dogs 
TK1) which can form surface S-S bridges resulting in oligomers formation. 
Dog TK1 most likely has a similar over all structure, but lacks Cys-206 at C-
terminal, and therefore may be less likely to form inter and intra disulfide 
bonds compared to human TK1. However, further studies are needed to 
understand the role of cysteines in formation of large MW complexes of TK1 
in serum. 
 
Summary (Paper II) 
 
Ø Dog recombinant TK1 was successfully cloned and expressed in 
E.coli and dog TK1 had 3 fold higher substrate specificity for AZT 
compared to human TK1. 
Ø Recombinant dog TK1 existed as oligomers after pretreatment with 
DTE and it is difficult to determine the MW of the active enzyme in 
the absence of reducing agent. 
Ø Recombinant human TK1 eluted as a major peak in the high MW 
fractions and DTE pre-incubation shifted the peak towards a lower 
MW region. 
Ø Cellular TK1 from humans and dogs eluted mainly as tetramers and 
pre-incubation with DTE inhibited dog cellular TK1 activity and had 
little effect on human cellular TK1. 
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Ø  Human and dog serum TK1 from patients with acute lymphocytic 
leukemia eluted as high MW oligomers and pre-incubation with DTE 
showed a reduction of the TK1 activity peak. 
Ø There was a proportion of 25 kDa TK1 polypeptide in fractions with 
no activity particularly for human serum TK1, demonstrating the 
presence of inactive TK1 protein in serum. 
Ø Extra cysteines in human TK1 could explain the differential behavior 
of TK1 from human and dogs in presence of reducing agents. 
 
7.3. Paper-III 
 
Properties of cellular and serum forms of thymidine kinase 1 (TK1) in 
dogs with acute lymphocytic leukemia (ALL) and canine mammary 
tumours (CMTs): implications for TK1 as a proliferation biomarker. 
 
In this study, the TK1 activity and TK1 protein levels in sera from dogs with 
mammary tumours were determined as well as the differences in the molecular 
forms of serum TK1 in canine lymphocytic leukemia and mammary tumours. 
An immunoaffinity assay described in Paper I was used to measure the TK1 
polypeptide (26 kDa protein) levels in CMT sera, and TK1 activity levels were 
determined by using optimized  [3H]-dT phosphorylation assay as described by 
Sharif et al. (2012). Fresh blood sample from ALL dogs and tissue from 
mammary tumour dogs as well as sera from the same dogs were collected and 
analysed for the cellular and serum forms of TK1 by using size exclusion 
chromatography. 
In total 20 healthy dogs and 27 dogs with CMTs classified as benign and 
malignant based on histological examination were included in the study. 
Overall, serum TK1 activity levels in CMTs were in the range of 0.5-1.8 
pmol/min/mL, which is significantly higher compared to the levels in healthy 
dogs. Serum TK1 protein levels were also significantly higher in sera from 
CMT patients compared to healthy dogs (Table 3). 
 
Table 3. Summary of serum thymidine kinase 1 activity and protein levels. 
  
  STK1 activity   (pmol/min/mL) STK1 protein (ng/mL) 
 Sample group           N       Median 
 
 Range Median   Range 
 Healthy           20          0.7 
 
0.4 - 1.4     8    3 - 18 
 Mammary adenoma           11          0.9 
 
0.5 - 1.5   26  12 - 39 
 Mammary 
carcinoma           13          0.9 
 
0.6 - 1.6   31  13 - 54 
 U.C (Un classified)             3          0.7 
 
0.5 - 1.8   17    9 - 28 
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A significant correlation was found between STK1 activity and TK1 protein 
levels in healthy and CMT samples (r = 0.52, P = 0.01; r = 0.41, P = 0.03, 
respectively). Furthermore, the TK1 protein assay differentiated sera from 
mammary adenomas efficiently from those of healthy dogs and adenomas from 
carcinomas. In contrast the TK1 activity assay could not distinguish sera from 
healthy dogs compared to mammary adenomas, and adenomas from 
carcinomas. ROC curve analysis showed that TK1 activity had sensitivity of 
22% while the TK1 protein assay of 80%. 
To understand the reason for high TK1 protein levels in CMTs, we collected 
CMT tissue along with sera from same patient and analysed TK1 by size 
exclusion chromatography. In parallel, we collected fresh blood sample from 
ALL dogs, isolated leukocytes and separated serum. The leucocytes 
(containing a high fraction of leukemic cells) were lysed and cytosolic proteins 
isolated and analysed.  
The TK1 enzyme activity and protein profiles in the cellular extract from the 
ALL patients showed a major peak in the MW range of 40-66 kDa, which is 
similar to what was observed in a previous study (Sharif et al., 2012). 
However, in the cellular extract from CMT tissue, a major peak corresponding 
to MW of 40-100 kDa and minor peak corresponds to 720-400 kDa were 
found. Western blot analysis demonstrated the TK1 polypeptide of 26 kDa in 
the fractions corresponding to the major peak and faint bands in the high MW 
region. 
The serum TK1 activity from the ALL patient eluted as a single peak in the 
high MW region (720-300 kDa) and western blot analysis showed the TK1 
polypeptide in same factions as the TK1 activity. In sera from CMT patients 
active TK1eluted as single peak similar to in the ALL case, but western blot 
analysis showed the TK1 protein bands in almost all fractions, indicating that 
TK1 exits in multiple forms in CMT (oligomers, dimers, and tetramers), with a 
large proportion of apparently inactive protein. The difference in the molecular 
forms of TK1 in ALL and CMT may explain the reason for high TK1 protein 
levels in the CMT sera but with relatively low TK1 activity. In healthy dogs, 
both TK1 activity and TK1 protein eluted as single peak in the high MW 
region. Moreover, the specific activity of serum TK1 (nmol dTMP/min/mg of 
TK1 of 26 kDa), based on the immunoaffinity assay and [3H]-dT activity 
measurements in healthy dogs was 2.5-fold higher than dogs with mammary 
tumours. Thus, there is a large fraction of inactive TK1 in CMTs. These results 
may improve the clinical utility of TK1 protein assays but further studies are 
warranted to determine the prognostic and monitoring capacity of TK1 protein 
assays. 
 
Summary (Paper III) 
 
Ø Serum TK1 protein and TK1 activity levels were significantly higher 
in dogs with mammary tumours compared to healthy dogs. 
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Ø The TK1 protein assays were able to differentiate dogs with mammary 
adenomas from healthy dogs, while the TK1 activity assays were not. 
Ø Cellular TK1 from ALL patients exists mainly as dimers while the 
serum TK1 from the same dog was mainly as high MW oligomers. 
Ø In CMT patients, TK1 from tumour tissue extracts eluted mainly as 
tetramer while serum TK1 from same patients exists in multimeric 
forms (dimer, tetramer and oligomers). 
Ø In healthy dogs, serum TK1 could only be detected in the high MW 
oligomer. 
Ø Differences in the molecular forms of serum TK1 in healthy, ALL and 
CMT dogs provides valuable information with clinical implications 
for the use of TK1 as a biomarker in veterinary medicine. 
 
 
7.4. Paper IV 
 
Development of a new ELISA for determining serum thymidine kinase 1 
protein levels in canine malignancies and its clinical significance 
 
The goal was to develop an ELISA for determining TK1 protein levels in sera 
from dogs with different malignancies. We also tested whether the TK1 protein 
levels could serve as a marker for monitoring treatment of canine lymphoma. 
The performance of TK1-ELISA was compared with that of the [3H]-dT 
phosphorylation assay.   
The TK1-ELISA is based on two antibodies raised against TK1 peptides from 
two of different regions, i.e. the C-terminal region of dog TK1, a highly 
conserved part of the active site of human TK1. Recombinant dog TK1 was 
used as standard. Dog specific polyclonal antibody was used to coat the 96-
well plates for catching serum TK1 and it is raised against the C-terminal 
region of canine TK1. The second biotinylated antibody, used for detection of 
the bound dog TK1, was a mouse monoclonal antibody raised against a peptide 
in the active site of human TK1 (Gasparri et al., 2009). Inter-assay and intra-
assay variations (CV %) of the prototype ELISA was estimated from the 
variability of duplicated samples is 5-15% and 5%, respectively. 
Serum samples from 30 healthy, 31 dogs with lymphoma, 5 dogs with 
leukemia and 40 dogs with solid tumours were analysed with the dog TK1 
ELISA. Furthermore, serum TK1 protein levels were also monitored in six 
lymphoma patients during chemotherapy. The results using STK1 activity 
assay and TK1-ELISA showed significantly higher TK1 levels (activity & 
protein) in sera from haematological malignancies compared to sera from 
healthy dogs (P < 0.0001) (Table 4). ROC curve analysis of TK1 activity assay 
had an AUC of 83% with a sensitivity of 75% and specificity of 96%. A 
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similar analysis of TK1-ELISA results showed an AUC of 94% with a slightly 
higher sensitivity of 78% and specificity of 96%. For dogs with solid tumours, 
there was no significant difference in STK1 activity levels compared to the 
healthy group. However, the STK1 protein levels were significantly higher in 
sera from dogs with solid tumours compared to healthy dogs (P < 0.0001). Sera 
from solid tumours were sub grouped as mammary tumours, mastocytomas, 
melanomas and others. The mean STK1 activity and STK1 protein levels in 
different sub groups were shown in Table 4. Solid tumour sub groups did not 
have higher median STK1 activity above the cut-off based on healthy. In 
contrast, STK1 protein levels of sub groups were above the healthy cut-off. 
These results were clearly demonstrated by ROC curve analysis as TK1 
activity assay had a sensitivity of 27% whereas the TK1-ELISA showed a 
sensitivity of 62%. Overall, the TK1-ELISA results correlated with the TK1 
activity values (rs = 0.64, P < 0.0001).  
TK1 protein levels along with TK1 activity were measured in lymphoma 
patients during chemotherapy and the TK1 protein levels returned to the 
normal range after treatment but in one dog with progressive disease the TK1 
protein and TK1 activity values continued to increase after treatments. These 
results indicate that TK1 protein determination during chemotherapy may help 
clinicians to monitor treatment and detect reoccurrence of tumours in early 
stages. 
 
Table 4. Serum thymidine kinase 1 activity and TK1 protein levels in dogs measured 
with the prototype ELISA. 
  
     STK1 activity 
   
 
      (pmol/min/mL) 
STK1-ELISA   
(ng/mL) 
 Group         N  Range Median     Range 
 
Median 
Healthy        30 0.7  - 1.4  1.02   0.07 - 0.47   0.25 
Lymphoma        31 0.54 -29.8  2.43   0.25 - 4.38   0.78 
Leukemia          5 1.33 - 58.7  38.3   0.33 - 4.19   3.92 
Mammary tumours        16 0.62 - 1.83  1.07   0.22 -1.5 
 
  0.50 
Mastocytoma          8 0.51 - 1.52  0.85   0.25 - 1.1 
 
  0.50 
Malignant Melanoma        11 0.52 - 1.52  1.15   0.21 - 3.40   0.53 
others          5 0.53 - 1.78  1.08   0.34 -1.13 
 
  0.67 
 
In this study, the TK1 activity values in sera from dogs with solid tumours 
were low, similar to previous studies (Sharif et al., 2012; von Euler et al., 2009; 
Nakamura et al., 1997). The higher TK1 protein levels in dogs with solid 
tumour strongly suggest that TK1 protein determinations are preferable to TK1 
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activity assays. The availability of a new ELISA should increase the clinical 
utility of TK1 as a proliferation biomarker. 
 
Summary (Paper IV) 
 
Ø A sandwich TK1-ELISA was developed using antibodies against from 
different regions of TK1 sequence. 
Ø TK1-ELISA is sensitive enough as TK1 activity assay to 
differentiate dogs with hematological tumors from healthy dogs. 
Ø In lymphoma patients, serum TK1 protein followed a similar pattern 
as the TK1 activity values during chemotherapy. 
Ø The TK1 activity assay could however not differentiate dogs with 
solid tumours from healthy dogs. 
Ø TK1-ELISA may be an alternative to TK1 activity assay for diagnosis 
of dogs with solid tumours. 
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8. Conclusions  
The results of this doctoral thesis contribute basic information about molecular 
properties of canine and human TK1 as well as provide new detection 
techniques of particular relevance for different canine malignancies.  
A major contribution was to establish immunoaffinity methods to determine 
the levels and molecular properties of the canine as well as human TK1 
polypeptide. These results indicate that STK1 activity assay would be valuable 
clinically for diagnosis and monitoring of haematological tumours. However, 
dogs with solid tumours had a low TK1 activity level, which in turn makes the 
clinical use of TK1 as biomarker less valuable. Here we developed an antibody 
based assay that measures TK1 subunit of 26 kDa protein levels in different 
canine malignancies. STK1 protein levels are significantly higher in dogs with 
haematological tumours and solid tumours compared to healthy dogs. This 
indicates that TK1 protein assays can be an alternative for TK1 activity assay 
especially for dogs with solid tumours. 
These methods were also used to define the differences between the molecular 
forms of recombinant, cellular and serum TK1 of humans and dogs by size 
exclusion chromatography. Recombinant and serum thymidine kinase 1 were 
shown to exist as high molecular weight oligomers of more than of 700 kDa as 
determined by both activity and the immunoaffinity assays. However, cellular 
TK1 from human or dog cells eluted mainly as dimers and tetramers. The 
presence of reducing agents produced important differences between the 
chromatographic behaviour of human and dog TK1 complexes, probably 
dependent on differences in inter and intra disulfide bonds. These differences 
could at least partly be explained by a lack of a cysteine in the C-terminal 
region of canine TK1. 
The results presented here showed that the TK1 protein assay had significantly 
higher ability to differentiate healthy dogs from dogs with mammary tumours 
compared to the activity assays, suggesting a clinical benefit with using the 
TK1 protein assay. This may thus help to identify tumour progression at an 
early stage. Furthermore important new basic information was obtained by 
size- exclusion chromatography, which convincingly demonstrated that there is 
a large fraction of inactive TK1 protein in case of sera from dogs with 
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mammary tumours. The reason for high TK1 protein in mammary tumours 
could be due to the tumour micro environment, characterized by oxidative 
stress, hypoxia and abnormal blood flow, which can induce changes in the 
structure of TK1 before it enters into the blood stream. This may results in 
inactivation of serum TK1. However, for ALL TK1 is directly released into 
blood from damaged cells, apparently leading to a more active form of serum 
TK1. This was shown for the first time in this thesis since we were able to 
determine the specific activities of serum TK1 in samples from dogs with ALL 
and mammary carcinoma.  
Even though TK1 protein assay appears to be valuable, it needs to be in a 
clinically compatible assay format allowing routine measurements. Attempts 
were therefore made to convert the immune affinity assay into an ELISA 
format. A prototype form of a sandwich TK1-ELISA, using TK1 antibodies 
from different regions, was developed. The TK1-ELISA showed similar 
sensitivity as the TK1 activity assay and could be used to clearly differentiate 
dogs with haematological tumours from healthy dogs. More importantly, the 
TK1 ELISA was also able to detect increased levels of SK1 in sera from dogs 
with several types of solid tumours, overcoming this previously shown 
limitation of the TK1 activity assay. Therefore, the TK1-ELISA is most likely 
clinically valuable for prognosis and monitoring of different malignant diseases 
in dogs.  
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9. Future research 
 
Ø One future goal is to make a mutational analysis of the cysteine 
residues in dog and human TK1. Human TK1 contains three additional 
cysteines and it is likely that Cys206 in the C-terminal region can form 
disulfide bridges with other proteins including other TK1 subunits. 
There is no cysteine in the homologous position in dog TK1. A 
systematic mutational analysis can help to define the role of cysteines 
in the TK1 oligomerzation process. 
Ø Even though the molecular forms of STK1 in sera from dogs with 
different tumours have been studied, further studies need to be done to 
clarify the relationship of these TK1 forms and staging. 
Ø Moreover, a detailed analysis of serum TK1 from ALL and CMT 
patients by 2D gel electrophoresis coupled with mass spectrometry 
should give important information on the nature of TK1 amino acid 
modifications. Further studies on the influence of different tumour 
microenvironment factors in various tumour types and stages should 
be carried out. This would give information about whether factors 
such as blood supply and oxygen availability can play vital role in the 
inactivation of serum TK1 in dogs with mammary tumours and other 
solid tumours. 
Ø The TK1-ELISA has to be validate further with a large group of 
clinical samples from different canine malignancies i.e. lymphomas, 
mammary tumours, malignant melanomas and other tumours, with 
serum samples taken at the time of diagnosis and during chemotherapy 
to determine the prognostic and monitoring ability of the TK1 protein 
assay. Furthermore, TK1-ELISA should most likely also be developed 
into a commercially available assay.  
Ø There is a need to determine whether the anti -TK1 antibodies can be 
used for histo-chemical expression studies and some attempts have 
already been made (von Euler & Eriksson, 2011).  
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